SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------------
FORM 10-K
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the fiscal year ended December 31, 1999 or
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from __________ to __________
COMMISSION FILE NUMBER 0-19732
CORVAS INTERNATIONAL, INC.
(Exact name of Registrant as specified in its charter)
DELAWARE 33-0238812
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation or organization)
3030 SCIENCE PARK ROAD, SAN DIEGO, CALIFORNIA 92121
(Address of principal executive offices, including zip code)
(858) 455-9800
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, $.001 Par Value
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities and Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
--- ---
Indicate by check mark if disclosure of delinquent filers pursuant to
Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of registrant's knowledge, in definitive proxy or information
statements incorporated by reference in Part III of this Form 10-K or any
amendment to this Form 10-K. [ ]
The approximate aggregate market value of the Common Stock held by
non-affiliates of the Registrant, based upon the last sale price of the Common
Stock reported on the Nasdaq National Market was $200,318,900 as of March 15,
2000.*
The number of shares of Common Stock outstanding as of March 15, 2000
was 21,060,206.
DOCUMENTS INCORPORATED BY REFERENCE
(To the extent indicated herein)
The Registrant's definitive proxy statement to be filed in connection with
solicitation of proxies for its Annual Meeting of Stockholders to be held on May
23, 2000 is incorporated by reference into Part III of this Form 10-K.
* Excludes 4,373,245 shares of common stock held by directors and officers and
stockholders whose beneficial ownership exceeds 10% of the shares outstanding at
March 15, 2000. Exclusion of shares held by any person should not be construed
to indicate that such person possesses the power, direct or indirect, to direct
or cause the direction of the management or policies of the Registrant, or that
such person is controlled by or under common control with the Registrant.
PART I
EXCEPT FOR THE HISTORICAL INFORMATION CONTAINED IN THIS REPORT, THE
FOLLOWING DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF
SECTION 27A OF THE SECURITIES ACT AND SECTION 21E OF THE EXCHANGE ACT,
INCLUDING, IN PARTICULAR, STATEMENTS IN THIS REPORT ABOUT OUR PLANS, STRATEGIES
AND PROSPECTS. THESE STATEMENTS, WHICH MAY INCLUDE WORDS SUCH AS "MAY," "WILL,"
"EXPECT," "BELIEVE," "INTEND," "PLAN," "ANTICIPATE," "ESTIMATE," OR SIMILAR
WORDS, ARE BASED ON OUR CURRENT BELIEFS, EXPECTATIONS AND ASSUMPTIONS AND ARE
SUBJECT TO A NUMBER OF RISKS AND UNCERTAINTIES. ALTHOUGH WE BELIEVE THAT OUR
BELIEFS, EXPECTATIONS AND ASSUMPTIONS AS REFLECTED IN THESE STATEMENTS ARE
REASONABLE, OUR ACTUAL RESULTS AND FINANCIAL PERFORMANCE MAY PROVE TO BE VERY
DIFFERENT FROM WHAT WE PREDICTED ON THE DATE OF THIS REPORT. FACTORS THAT COULD
CAUSE OR CONTRIBUTE TO SUCH DIFFERENCES INCLUDE, BUT ARE NOT LIMITED TO, THOSE
DISCUSSED IN "RISK FACTORS," AS WELL AS IN THE SECTIONS ENTITLED "BUSINESS
STRATEGY," "PRODUCT DEVELOPMENT PROGRAMS," "INTEGRATED TECHNOLOGY PLATFORMS,"
"STRATEGIC ALLIANCES," "PATENTS AND PROPRIETARY RIGHTS," AND "MANAGEMENT'S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS."
IN THIS FORM 10-K, "CORVAS," "WE," "US" AND "OUR" REFER TO CORVAS
INTERNATIONAL, INC.
ITEM 1. BUSINESS
OVERVIEW
Corvas is a clinical-stage biopharmaceutical firm engaged in the design
and development of a new generation of therapeutic agents for cardiovascular,
cancer, stroke and other major diseases. Two of our drug candidates are in Phase
II clinical trials. Our drug candidates target major cardiovascular diseases
such as heart attack, unstable angina, or UA, deep vein thrombosis, or DVT, and
pulmonary embolism, or PE, as well as cancer and acute inflammation associated
with reperfusion injury in ischemic stroke. We have developed our portfolio of
drug candidates by integrating our in-depth knowledge of the biology of blood
clot formation (thrombosis), inflammation and, more generally, tumor vascular
biology with advanced and proprietary drug discovery and design technology.
Our drug design programs focus on the inhibition and modulation of
protease enzymes involved in disease. We base our drug design programs on two
technology platforms: medicinal chemistry and novel protein (biologics)
discovery. We use our medicinal chemistry programs to design synthetic drug
candidates having oral activity. Our platform of novel biologics discovery,
including gene discovery, molecular cloning, expression and mutagenesis, enables
us to identify and improve upon naturally-occurring novel proteins as drug
candidates and move them into clinical development. We have demonstrated the
ability to exploit various protease enzymes in the discovery of novel drugs for
cardiovascular disease, cancer, and infectious diseases such as hepatitis C and
malaria. We are using our expertise of protease modulation as the basis for our
ongoing efforts in the development of a new generation of oral and injectable
anticoagulants, as well as new cancer, anti-viral and anti-parasitic therapies.
All of our drug candidates are still in the research and development
stage. We are currently conducting the following human clinical trials.
o An international, multi-center Phase II trial of our
proprietary injectable anticoagulant rNAPc2 for the prevention
of DVT, which is the formation of blood clots in the veins of
the legs that can follow orthopedic surgery.
o A multi-center Phase IIa trial of rNAPc2 in coronary care
patients undergoing elective coronary balloon angioplasty.
-2-
One of our corporate partners, Pfizer Inc., has recently completed
patient enrollment in a Phase IIa trial of UK-279,276, previously designated as
recombinant neutrophil inhibitory factor, or rNIF. This drug candidate,
discovered at Corvas, is being developed as a possible stroke therapy. Phase II
efficacy trials are planned to begin in the second half of 2000, with the
potential for accelerated development.
In addition to our alliance with Pfizer for UK-279,276, we also have
two strategic alliances with Schering Corporation, or Schering-Plough. The first
collaboration is for the development of synthetic oral anticoagulants for the
prevention and treatment of chronic cardiovascular diseases involving
thrombosis, such as DVT, UA, atrial fibrillation (which is a risk factor for
stroke) and myocardial infarction, or heart attack. We are also collaborating
with Schering-Plough on a program directed at the development of oral inhibitors
of a key protease associated with hepatitis C virus replication, intended to
prevent and treat this chronic viral disease.
We have expanded our internal research efforts to include two new key
targets for the treatment of specific types of solid tumor cancers. This
research is focused on the development of drugs that may inhibit the formation
of new blood vessels (angiogenesis) and the migration of tumor cells to other
tissues (metastasis) associated with these solid tumors. In addition, we have
begun a program aimed at discovering novel proteases in various cancer tissues,
using gene cloning as potential new targets for drug development. Another of our
new research programs, being funded through a $599,000 government grant, is
directed towards discovering inhibitors of a key malaria protease, falcipain.
CARDIOVASCULAR PROGRAMS. We have focused our cardiovascular programs on
the development of both synthetic small molecule drugs and drugs based on
naturally-occurring proteins that inhibit blood clot formation and certain
inflammatory processes. Our programs are directed at inhibiting serine
proteases, specifically thrombin, Factor Xa and Factor VIIa, which are all key
enzymes in the blood coagulation cascade.
The primary goal of our synthetic anticoagulant program is to develop
safe and effective drugs that can be taken in pill form to be used in various
clinical indications, including the prevention of strokes in patients with
chronic atrial fibrillation, the prevention of complications following a heart
attack, and the prevention and treatment of chronic DVT. We are developing these
drug candidates in collaboration with our partner Schering-Plough.
-3-
Corvas scientists have discovered a novel class of naturally-occurring
small protein anticoagulants called Nematode Anticoagulant Proteins, or NAPs, in
blood-feeding hookworms. These proteins inhibit either Factor Xa or Factor VIIa
complexed with its non-enzymatic co-factor, Tissue Factor, or Factor VIIa/Tissue
Factor. rNAPc2 is a member of the NAP family that inhibits the Factor
VIIa/Tissue Factor complex, which initiates the first step in the blood
coagulation cascade leading to blood clot formation. We have completed two Phase
I clinical trials to evaluate the safety of rNAPc2 and, in December 1998, we
began an international, multi-center Phase II trial which is ongoing. The
primary objective of this trial is to demonstrate the ability of rNAPc2 to
prevent DVT, the formation of blood clots in the veins of the legs that can
occur following orthopedic surgery, and subsequent PE, which is a serious and
often fatal condition in which part of the blood clot formed in the leg travels
to the lungs and blocks the blood supply to the heart. In late 1999, we began a
Phase IIa trial of rNAPc2 in patients undergoing elective percutaneous
transluminal coronary angioplasty, or PTCA, with and without stent placement.
The primary objective of this trial is to establish the safety of rNAPc2 in
patients undergoing PTCA. We intend to use this data to design a subsequent
clinical trial to evaluate rNAPc2 in patients suffering UA since a large
percentage of UA patients undergo coronary intervention such as PTCA and stent
placement. Additionally, a Phase I trial in which rNAPc2 is being administered
to patients with disseminated intravascular coagulation, or DIC, has also been
ongoing in order to examine the safety, tolerability and pharmacokinetics in
patients with an active coagulation disorder. To date, we have not partnered
with any collaborators on this program and have retained all commercialization
rights to this compound. We are currently seeking an appropriate corporate
partner or partners for the development and commercialization of all or part of
the NAP program.
Another of our proprietary drug candidates, rNAP5, which inhibits
Factor Xa, is ready to begin Phase I clinical testing for acute cardiovascular
indications, pending establishment of a partnership arrangement or corporate
collaboration for this program.
Our cardiovascular program also includes a drug candidate for the
prevention of the acute inflammatory response that often occurs after the onset
of an ischemic stroke. This inflammatory response can exacerbate damage to
injured areas of the brain. We discovered the protein called neutrophil
inhibitory factor, or NIF, from the same blood-feeding hookworms as NAP, and
determined that it blocks certain white blood cell (neutrophil) functions
associated with acute inflammation. In 1997, we entered into a license and
development agreement with Pfizer for rNIF, now referred to by Pfizer as
UK-279,276. Pfizer has recently completed patient enrollment in a Phase IIa
trial in patients suffering from ischemic stroke, and has announced plans to
begin efficacy trials in the second half of 2000. See "- Strategic Alliances."
CANCER PROGRAMS. We believe that we can use our proprietary
combinatorial chemistry approach and expertise in protease inhibition that we
developed in connection with our thrombosis programs to develop drugs outside
the cardiovascular field. This technology allows us to develop synthetic
libraries dedicated to mechanism-based inhibitors specifically targeted at
cysteine and serine proteases. We are currently using this approach in our
cancer programs, where our research is focused on the development of synthetic
drugs that may inhibit the formation of new blood vessels, or angiogenesis, and
the metastatic migration of tumor cells in certain solid tumors. The urokinase
plasminogen activator, or uPA, protease has been associated with tumor
metastasis and angiogenesis in certain solid tumors. Lead inhibitors in this
program have been shown to inhibit angiogenesis and tumor growth in animal
models.
-4-
Another of our cancer programs is directed towards Plasminogen
Activator Inhibitor-1, or PAI-1, antagonists. PAI-1 is the primary serpin
inhibitor in plasma controlling the activity of the proteases Tissue-type
Plasminogen Activator, or tPA, and uPA. Elevated levels of PAI-1 have been shown
to directly correlate with a poor outcome in certain cancers, particularly in
breast cancer. This program has moved beyond the lead identification stage and
is now focused on optimizing compounds for studies in animal models of cancer.
The role of PAI-1 in controlling the activity of uPA and tPA extends the
potential use of antagonists for the prevention and treatment of cardiovascular
diseases such as atherosclerosis and myocardial infarction.
Our third program in cancer is focused on the discovery of novel
proteases involved in solid tumor growth, angiogenesis and metastasis. This
early-stage research program, which uses molecular gene cloning technology, has
produced several new serine proteases that are bound to the surface of tumor
cells. Lead inhibitors to a select number of these proteases have been
identified using our synthetic combinatorial protease inhibitor technology. The
rapid identification of new proteases and lead inhibitors will allow us to
determine if these new proteases are relevant targets for potential new cancer
therapies using established models of solid tumor cancer.
OTHER PROGRAMS. In collaboration with Schering-Plough, we have a
program directed at a serine protease associated with replication of the
hepatitis C virus. This program covers the development of oral inhibitors of
this protease. See "- Strategic Alliances."
One of our newer research programs is directed towards discovering
synthetic inhibitors of a crucial protease involved in the pathogenic effects of
malaria protease inhibitors. This early-stage program, aimed at developing a
novel therapy for this devastating disease, is being funded by a government
grant from the National Institute for Allergy and Infectious Disease.
CORVAS(R) is a registered trademark and the Corvas logo is a trademark
of the Company. COUMADIN(R) is a registered trademark of DuPont Pharmaceuticals
Company. REOPRO(R) is a registered trademark of Eli Lilly and Company. PLAVIX(R)
and ARSUMAX(R) are registered trademarks of Sanofi-Synthelabo Inc. TICLID(R) and
LARIAM(R) are registered trademarks of Hoffmann-La Roche Inc. ACTIVASE(R) is a
registered trademark of Genentech, Inc. AGGRASTAT(R) is a registered trademark
of Merck & Co., Inc. MALARONE(R) is a registered trademark of Glaxo Wellcome
plc. RIAMET(R) is a registered trademark of Novartis Pharma. VIRAZOLE(R) is a
registered trademark of ICN Pharmaceuticals, Inc. LOVENOX(R) is a registered
trademark of Aventis Pharma AG. INTEGRELIN(R) is a registered trademark of COR
Therapeutics, Inc. NOVOSEVEN(R) is a registered trademark of Novo Nordisk
Pharmaceuticals, Inc.
-5-
BUSINESS STRATEGY
We believe our technical expertise will allow us to continue to
efficiently discover and develop new therapeutic drug candidates and advance
them to the clinic. In addition, we believe we can use our drug development
skills in medicinal chemistry and molecular biology, along with our skills in
pharmacology and clinical development, to diversify our portfolio of proprietary
and partnered drug candidates.
Key elements of our strategy include:
ADVANCE COMPOUNDS TO THE CLINIC. Corvas is focusing on advancing drug
candidates from the research and development stage into the clinic in an
efficient and practical manner. Alone or with our strategic alliance partners,
we conducted four clinical trials on two drug candidates in 1999. Two Phase II
trials of our proprietary drug candidate rNAPc2 are currently ongoing. An
additional Phase II efficacy trial of UK-279,276 (previously designated as rNIF)
is expected to begin in the second half of 2000. We believe our research and
development programs will continue to provide new drug candidates that we can
advance to the clinic in the future, either alone or with strategic partners.
DEVELOP A COMPREHENSIVE PORTFOLIO OF ANTITHROMBOTIC DRUG CANDIDATES. We
continue to develop a broad range of antithrombotic drug candidates to address
both the chronic and acute cardiovascular markets. We believe that our programs
on the development of inhibitors of blood coagulation proteases will enable us
to target multiple clinical indications with drugs that can be administered in
pill form or by injection.
EXPAND THE PRODUCT PORTFOLIO BY APPLICATION OF TECHNOLOGY TO ADDITIONAL
TARGETS. We intend to expand on our success in developing small molecule
inhibitors of serine proteases that can be administered orally or by injection.
Further, we believe we can use this existing knowledge base to discover and
develop new inhibitors of related proteases in the serine and the
closely-related cysteine protease family. For example, we have identified
compounds with inhibitory activity against the hepatitis C NS3 protease, uPA and
the malarial protease falcipain. We plan to use our proprietary chemical
methodologies and molecular biology to increase the speed and economy of new
lead discovery in the area of protease inhibition and expand the number of
target proteases in our portfolio.
INTEGRATE DRUG DISCOVERY METHODOLOGIES. We intend to continue to
integrate a wide range of disciplines to develop new drug candidates through a
systematic process. Our drug development disciplines include medicinal
chemistry, combinatorial chemistry, computer-aided drug design, structural
biology, molecular biology, biochemistry, as well as pharmacology competencies.
ESTABLISH A STRONG PORTFOLIO OF PATENTS AND PROPRIETARY TECHNOLOGIES.
We plan to continue our proactive policy of filing and prosecuting patent
applications claiming a range of inventions, including a number of new chemical
classes of compounds, uses and methods of synthesis of new molecules, discovery
methods, novel genes and gene products, and novel analytical reagents. We have
entered into selected agreements to license enabling technology from third
parties and intend to seek rights to additional external technology on an
ongoing basis to complement internal discovery efforts. See "- Patents and
Proprietary Rights" and "- Strategic Alliances."
-6-
USE STRATEGIC ALLIANCES AS A MEANS TO ENHANCE DEVELOPMENT AND
COMMERCIALIZATION OF PRODUCTS. We intend to continue to establish strategic
alliances, such as those already established with Schering-Plough and Pfizer, to
access the resources required to support the development of other technologies
and drug candidates and the commercialization of drugs. We may seek to retain
certain exclusive, joint commercialization or co-promotion rights to selected
acute care products for the U.S. market or other selected markets.
BACKGROUND
THROMBOSIS
The formation of a blood clot, or thrombus, results from a complex
cascade of biochemical events involving proteases, co-factor proteins and
cellular fragments called platelets. Although blood clot formation is a normal
vascular repair mechanism, under circumstances of disease and narrowing, it can
also result in occlusion of one or more critical blood vessels (thrombosis) in a
vital organ, such as the heart, lungs or brain. The blood coagulation process is
most often triggered when there is damage or disruption to the lining of the
blood vessel wall known as the endothelium. Damage or disruption of the
endothelium exposes the previously protected underlying tissue of the blood
vessel wall to the blood. Exposure of the protein Tissue Factor to blood
triggers the formation of a complex with the serine protease Factor VIIa, which
is circulating in the blood. The resulting complex (Factor VIIa/Tissue Factor)
initiates a complex biochemical cascade of events leading to the development of
a blood clot that involves the formation of another key serine protease, Factor
Xa. Factor Xa carries out the penultimate step in this cascade, which is the
formation of the final serine protease thrombin. It is thrombin that causes the
formation of the blood clot at the site of the blood vessel damage by activating
platelets and forming a glue-like protein fibrin.
Several significant clinical conditions involving thrombosis can be
characterized by the location of the blood vessel where the clot is lodged. For
example, acute myocardial infarction, or MI, results from the formation of an
occlusive blood clot in a major coronary artery that supplies blood to the heart
muscle. Transient occlusive thrombosis in one or more of the coronary arteries
of the heart may result in UA, which leads to serious chest pain and is a
significant risk factor in the development of MI. Stroke or transient ischemic
attacks, also known as TIA's, may result from thrombosis in an artery that
supplies blood to a part of the brain. Similarly, thrombosis in the major veins
of the legs (DVT) causes local inflammation, pain and other complications,
including the potential for dislodgment of part of the blood clot which can
travel to the lungs and may result in life-threatening PE. DVT and PE can be
unpredictable complications of surgery that directly or indirectly involve the
vasculature, such as major orthopedic and abdominal surgery, respectively, as
well as neurosurgery. Thrombosis can also be generalized systemically, with
microclot formation occurring throughout the circulatory system. This condition,
known as DIC, can be a consequence of systemic inflammation caused by bacterial
and/or viral infection as seen in bacterial sepsis, or in infection by
hemorrhagic viruses such as ebola, and is also a complication of certain types
of cancer that may result in multiple organ failure, uncontrolled hemorrhage and
death.
Two classes of antithrombotic drugs are presently in clinical use:
anticoagulants and antiplatelet agents. In the U.S., heparins and warfarin
(COUMADIN(R)) are the only drugs currently approved for use as acute and chronic
anticoagulants, respectively. Although these drugs are widely prescribed, they
have significant limitations. Unfractionated heparins, or UFH, which act by an
indirect inhibition of one or more coagulation proteases (primarily thrombin),
-7-
can cause excessive bleeding and decreased platelet count and are administered
primarily by intravenous infusion in a hospital setting where monitoring is
available. Low molecular weight heparins, or LMWH, which are derived from UFH,
are injected subcutaneously and do not require monitoring of coagulation
function; these are the anticoagulants of choice today for acute therapy.
Although LMWHs have been adopted for selected indications and have the advantage
of subcutaneous injection, this class of anticoagulants still suffers from many
of the limitations of UFH and has shown limited efficacy in several clinical
indications of thrombosis. Warfarin, which is administered orally, lacks
specificity of action, may cause bleeding, must be carefully monitored and, due
to its slow onset of action, is unsuitable for use as an acute antithrombotic
drug. Additionally, there are many adverse drug and dietary interactions that
impact the effectiveness of warfarin due to the difficulties in maintaining
effective blood levels of the drug which in turn narrows the margin of safety
for effective use.
Aspirin, the most commonly used antiplatelet agent for chronic therapy,
has a relatively slow onset of action and its effect is reversed by the natural
production of new blood platelets, a process that takes approximately ten days.
In addition, chronic administration of aspirin carries the risk of
gastrointestinal bleeding (ulceration) and possibly hemorrhagic stroke. Two
other antiplatelet agents are currently marketed for chronic therapy, but offer
only a marginal benefit over aspirin. Clopidogrel (TICLID(R)) and ticlopidine
(PLAVIX(R)) are chemically related drugs that act to reduce the activity of
platelets. INTEGRELIN(TM), REOPRO(R) AND AGGRASTAT(R) are products in a new
class of antiplatelet agents, GPIIb/IIIa antagonists, which have been introduced
to the market for acute coronary thrombotic indications. The GPIIb/IIIa
antagonists are administered intravenously and must be used with an
anticoagulant such as UFH.
Thrombotic and associated vascular diseases affect large numbers of
patients. Limited efficacy, adverse side effects and invasive methods of
administration burden existing products, which provides a significant market
opportunity for new drugs. The growth in sales in the antithrombotic drug
category supports the view that physicians are adopting new agents in search of
more effective and safer agents with better therapeutic outcomes and economics.
We are building on recent scientific advances in the understanding of the
mechanisms of blood clot formation and are developing new drugs designed to
intervene more specifically in the disease process. This may result in a new
generation of drugs that we believe will offer important economic and
therapeutic advantages over existing therapies.
INFLAMMATION
Inflammation is the body's response to injury and infection. The
inflammatory response is mediated by a series of biochemical events by which the
body attempts to limit or destroy the injurious agents, heal wounds and maintain
health. However, the body's inflammatory response can result in significant
additional tissue injury. A critical event in an inflammatory response is the
adhesion of neutrophils, a specific type of white blood cell, to the
endothelium, which lines the surface of the blood vessel walls. Adhesion is
caused by the interaction of specific receptors on the neutrophils with adhesion
molecules on the endothelium. After adhesion occurs, the neutrophils migrate
across the lining of the blood vessel and into the underlying tissue where they
release toxic substances that, under normal conditions, eliminate foreign
substances such as bacteria but, in certain disease states, can exacerbate
damage to normal tissue. These events can occur in both acute and chronic
inflammatory conditions. Acute disorders that are often accompanied by this
inflammatory response include ischemic stroke and the traumatic shock that can
occur following certain surgical procedures such as aortic aneurysm repair,
artery bypass grafting and major abdominal surgery.
-8-
The competitive environment in the treatment of stroke is presently
favorable for new product entry. Physicians have few drugs at their disposal for
treating the stroke patient. Currently marketed anti-inflammatory drugs seek to
alleviate symptoms rather than intervene in the underlying disease processes. In
the acute phase of ischemic stroke, a thrombolytic agent, ACTIVASE(R), may be
given to attempt to dissolve the blood clot that is blocking blood flow and
causing the ischemia. However, this treatment does not prevent, and may
initiate, the secondary, and often serious, damage that occurs when blood flow
is restored (reperfusion injury). Blocking the activation and adhesion of
neutrophils to the endothelium, and thereby preventing their accumulation in
tissue, is an alternate approach that we believe could more effectively inhibit
the inflammatory response responsible for reperfusion injury.
Along with our partner Pfizer, we are developing a drug that is
intended to block the activation and adhesion of neutrophils in response to an
ischemic stroke, thereby inhibiting the inflammation that may cause additional
damage to the affected portion of the brain. Development programs at other
companies have also addressed neutrophil receptor inhibition exclusively using
antibody-based agents. Although some of these programs have been discontinued,
we believe, because of limited efficacy or unfavorable side-effect profiles,
other of our competitors are continuing in clinical trials.
CANCER
The cancer products that are available are diverse, but are generally
characterized by limited efficacy or significant and debilitating side effects.
In solid tumor cancers, malignant tumor cells invade and disrupt nearby tissues
and can also metastasize, or spread to other organs far beyond the primary tumor
mass. The metastasis of these tumors to vital organs, such as the lungs and the
liver, is frequently the leading cause of mortality in patients with solid tumor
cancer. Surgery can be effective if the cancer has not metastasized and is often
used to remove the primary solid tumor mass if it is accessible to the surgeon.
Radiation therapy also can be employed to irradiate a solid tumor and
surrounding tissues and is a first-line therapy for inoperable tumors, but side
effects are a limiting factor in treatment. Radiation therapy is used frequently
in conjunction with surgery either to reduce the tumor mass prior to surgery or
to destroy tumor cells that may remain at the tumor site after surgery. However,
radiation therapy cannot assure that all tumor cells will be destroyed and has
only limited utility for treating widespread metastases. While surgery and
radiation therapy are the primary treatments for solid tumors, chemotherapy and
hormonal treatments are often used as adjunctive therapies and are also used as
primary therapies for inoperable or metastatic cancers. There are many,
well-established marketers of products for radiation, chemotherapy and hormonal
treatments. However, the side effects of these therapies can often limit their
effectiveness due to patient tolerance and compliance.
We are focusing on the development of drugs that inhibit the growth of
new blood vessels required for rapid growth of the primary tumor, as well as
strategies for blocking the migration and growth of metastatic tumor cells to
other organs.
-9-
ROLE OF UROKINASE PLASMINOGEN ACTIVATOR
---------------------------------------
The process of metastatic migration of tumor cells is not presently
well understood. However, it has been demonstrated that several proteases may
play an important role in this process. uPA is a serine protease similar to the
serine proteases in the blood coagulation cascade that has been shown to play an
important role in the metastasis of certain solid tumor types. In addition, uPA
has been implicated in the establishment and growth of the new blood vessels
required for the growth of the primary tumor mass and survival of metastatic
tumors in organs and tissues distant from the primary tumor. We believe that the
multiple effects of uPA in the metastasis and growth of certain solid tumors, as
well as its similarities to other serine proteases, make it an ideal target for
us to develop as a selective inhibitor that may be used in conjunction with
first-line therapies for patients with life-threatening malignancies.
ROLE OF PLASMINOGEN ACTIVATOR INHIBITOR-1
-----------------------------------------
The protein Plasminogen Activator Inhibitor-1, or PAI-1, is a natural
serpin-type protease inhibitor primarily found in the circulation and in the
blood vessel wall that regulates the activity of the plasminogen activators tPA
and uPA. One function of PAI-1 is to regulate the activity of tPA and, to a
lesser extent, uPA from dissolving blood clots too rapidly. The modulation of
tPA inhibition by PAI-1 may be the basis for improving the effectiveness of this
thrombolytic agent in the treatment of acute MI. Additionally, the chronic
antagonism of PAI-1 activity may be an alternative to the use of anticoagulants
since such a compound would be expected to improve the body's ability to
dissolve blood clots more effectively. New research in academic laboratories has
suggested that PAI-1 may play a key role in the susceptibility of the
atherosclerotic plaque in blood vessels of the heart to rupture, leading to
serious complications such as UA and MI. This may be particularly true in
patients with Type II diabetes.
The role of PAI-1 in the natural progression of certain solid tumor
cancers has been suggested based on the strong correlation of increased levels
of this protein and a poor patient survival in certain types of cancer,
including breast cancer. In addition, recent evidence derived from animals that
are genetically lacking PAI-1 has demonstrated that the growth and metastasis of
certain human tumors is significantly impaired, suggesting that PAI-1 may play a
pivotal role in the growth and metastatic migration of certain solid tumors.
Accordingly, PAI-1 appears to be an appropriate target for the development of
new drugs as specific antagonists to this serpin inhibitor that could be used in
conjunction with other therapies for the treatment of patients with
life-threatening tumors, as well as certain chronic cardiovascular diseases.
-10-
ROLE OF CANCER PROTEASES
------------------------
The role of proteases in the growth and metastasis of solid tumor
cancers is well established. As discussed above, the protease uPA has been
implicated in angiogenesis and metastasis. The proteolytic effects of uPA are
mediated on the surface of the certain cancer cells that have a specific
receptor (uPA-receptor, or uPAR) that is bound to the membrane of the cancer
cell. Recent evidence in the scientific literature has suggested that there may
be other surface or membrane-bound proteases that, like uPA, may be important in
tumor growth and progression. But unlike uPA, these proteases are themselves
bound to the membrane of the tumor cells and, as such, express their proteolytic
activity without an associated receptor. It is unclear what extent this new
class of membrane-bound proteases plays in solid tumor biology. However, it is
unlikely that these membrane-bound proteases are simply playing a bystander role
since the few members of this class that have been identified thus far appear to
be up-regulated, or present at higher levels, in certain solid tumors compared
to normal tissues. The identification of these new membrane-bound solid tumor
proteases, coupled with the discovery of chemical and monoclonal antibody
inhibitors, may lead to one or more novel targets for treatment of primary and
associated metastatic tumors.
HEPATITIS C
Chronic hepatitis C infection is a substantial public health problem
affecting a significant percentage of the world's population. Infection with the
hepatitis C virus may lead to development of serious and, in some cases,
life-threatening chronic liver disease including liver failure and cancer. The
primary treatment for hepatitis C infections today is a regimen of alpha
interferon, a recombinant anti-viral protein, and other anti-viral drugs such as
ribavirin (VIRAZOLE(R)). The leading alpha interferon-ribavirin combination is
marketed by Schering-Plough, Corvas' strategic partner on its hepatitis C
program. The marketed products demonstrate efficacy in only a minority segment
of patients, are expensive, must be administered by subcutaneous injection
several times weekly and are, at times, associated with undesirable side
effects. Development efforts by other biotechnology and pharmaceutical companies
include attempts to develop vaccines, broad-spectrum anti-viral agents and other
small molecule agents that may be taken in pill form and focus on molecular
targets that are crucial to the replication of the virus. One such target is a
serine protease made by the virus to facilitate its replication in the host
liver cells. We believe that development of a pill that inhibits this serine
protease may be an effective means of treating patients with chronic hepatitis C
infection.
PARASITIC DISEASES - MALARIA
Malaria is a parasitic affliction that has seen a resurgence in
infection rates over the last decade. Over 40% of the world's population is
possibly at risk, with greater than 500 million individuals becoming infected
each year. Annual mortality rates, currently at 2.7 million people worldwide,
have been steadily increasing primarily due to increased resistance of the
malaria parasite (primarily the PLASMODIUM species FALCIPARUM and VIVAX) to
existing therapeutic drugs. The global effects of malaria significantly threaten
public health and, more importantly, economic growth and prosperity in many
third world countries with an emerging middle class economy, as well as more
affluent travelers and military personnel in Western and other non-endemic
countries. This is the basis for the ROLL BACK MALARIA INITIATIVE, a worldwide
effort being organized by the World Health Organization, or WHO, to re-focus
efforts on the development of new approaches in the prevention and treatment of
malaria.
-11-
Efforts continue to be directed at the development of a vaccine, but
there has been little success in this area to date. The current class of
therapeutic anti-parasitic drugs is becoming less effective due to resistance.
The current drug of choice in most Western nations for prevention during travel
to endemic countries is mefloquine (LARIAM(R)). Reported neurological problems
associated with this drug, however, are limiting its routine use. Generic
versions of the established anti-parasitic drugs chloroquine and proguanil are
in more widespread use, but resistance is beginning to limit their effectiveness
as well. The newest therapeutic drugs introduced into use, primarily in Europe
and parts of Africa and Asia, are MALARONE(R) and the artemisinin derivatives,
ARSUMAX(R) and RIAMET(R). While these agents are proving to be effective in
limited areas, it remains to be seen whether they will be suitable for
widespread use.
The life cycle of the malaria parasite offers several attractive
targets for drug intervention, including the key cysteine protease, falcipain.
The malaria parasite uses falcipain to aid in the digestion of hemoglobin
following infection of the red blood cells. In animal models, inhibition of
falcipain has been demonstrated to inhibit parasite development and replication,
allowing it to be cleared from the body. Specific inhibitors of this protease
would be expected to yield a possible new generation of anti-malarial drugs for
the prevention and treatment of this dreaded worldwide disease. Additionally,
the existence of proteases similar to falcipain in other parasites that cause
significant human disease worldwide including Chagas disease, Leishmaniasis and
Schistomiasis, offer the possibility that the approach taken with malaria may be
applicable to the development of new therapies for these and other diseases
impacting the world.
-12-
PRODUCT DEVELOPMENT PROGRAMS
The following table describes our primary drug development programs,
their targeted therapeutic indications and their current development status.
- ---------------------------------------------------------------------------------------------------------------------------------
PROGRAM TARGET INDICATION STATUS PARTNER
- ---------------------------------------------------------------------------------------------------------------------------------
CARDIOVASCULAR:
FACTOR VIIA/TISSUE FACTOR INHIBITOR
- -----------------------------------
rNAPc2-injectable DVT/PE, UA, MI Phase II for DVT/PE; Corvas proprietary
Phase IIa in angioplasty
patients
FACTOR Xa INHIBITOR
- -------------------
rNAP5-injectable DVT/PE, MI, UA Ready for Phase I, pending Corvas proprietary
collaboration
FACTOR Xa/THROMBIN INHIBITORS
- -----------------------------
Oral Anticoagulants MI, UA, DVT/PE Lead Schering-Plough
evaluation/optimization
ANTI-INFLAMMATORY
- -----------------
UK-279,276 (rNIF)-injectable Ischemic stroke Phase II Pfizer
CANCER:
Urokinase (uPA) Protease Tumor metastasis, Lead Corvas proprietary
Inhibitors tumor angiogenesis evaluation/optimization
Plasminogen Activator Tumor metastasis, Lead Corvas proprietary
Inhibitor-1 (PAI-1) solid tumor cancers evaluation/optimization
Antagonists
Cancer Proteases Tumor growth, tumor Lead discovery Corvas proprietary
metastasis
OTHER:
Hepatitis C NS3 Protease Chronic hepatitis C Lead Schering-Plough
Inhibitors infections evaluation/optimization
Falcipain Protease Inhibitors Malaria vaccine Lead Corvas proprietary
evaluation/optimization
- ---------------------
The following abbreviations are used for target indication in the above table:
DVT=deep vein thrombosis; MI=myocardial infarction; PE=pulmonary embolism;
UA=unstable angina.
The following definitions of status apply to the above table: "Lead
discovery"=Identification of lead compounds with activity in appropriate IN
VITRO assay systems. These lead compounds may require additional chemical
manipulation and more extensive evaluation prior to selection of candidates, if
any, for preclinical development. "Lead evaluation/optimization"= Extensive
evaluation of lead compounds in multiple IN VITRO assay systems and preliminary
animal pharmacology studies. See "Business - Government Regulation" for a
description of the clinical trial process.
-13-
CARDIOVASCULAR PROGRAMS
We are developing a new generation of drug candidates for the
prevention and treatment of a broad range of acute and chronic thrombotic
indications, as well as an anti-inflammatory agent directed at ischemic stroke.
A comprehensive approach is used in our cardiovascular program, strategically
targeting inhibition of multiple key proteases in the coagulation cascade. We
are developing compounds for the inhibition of thrombin, Factor Xa, and Factor
VIIa/Tissue Factor, and believe that these drug candidates have advantages over
currently available antithrombotic drugs with respect to efficacy, patient
safety and convenience. We also believe that our program targeting the
inhibition of the key coagulation proteases is among the most comprehensive in
the industry and that we have achieved a leading position in the design and
development of injectable and oral antithrombotic agents.
NAP ANTICOAGULANTS. Our scientists have discovered a unique family of
small protein inhibitors of Factors Xa and VIIa/Tissue Factor. The NAP proteins
were discovered by Corvas scientists in the hookworm parasite that has evolved
efficient anticoagulation mechanisms allowing it to continuously feed on blood.
Based on comparative data developed both in our laboratories and with
collaborators, we have shown that these agents exhibit significant
antithrombotic potency. A recombinant version of NAPc2 (rNAPc2), a novel
inhibitor of Factor VIIa/Tissue Factor, has completed two Phase I clinical
trials to assess safety, tolerability and pharmacokinetics following single and
multiple subcutaneous administrations. The route of administration of rNAPc2 is
subcutaneous injection, which is similar to LOVENOX(R), a LMWH that is the
current leading clinical anticoagulant for acute therapy. The administration of
rNAPc2 in these double-blinded, placebo-controlled studies resulted in a
dose-dependent systemic anticoagulant effect with a prolonged duration of
greater than 50 hours. There were no safety or tolerability concerns associated
with the administration of rNAPc2 at any of the doses tested. A third Phase I
trial was completed in which recombinant Factor VIIa (NOVOSEVEN(R)) was shown to
transiently reverse the anticoagulant effects of rNAPc2 in normal male
volunteers, which suggests that it may be an acceptable agent to restore normal
hemostasis in cases where the reversal of the anticoagulant effect of rNAPc2 is
required. An additional Phase Ib trial is in progress in patients presenting to
the clinic with DIC in order to examine safety, tolerability and
pharmacokinetics in patients with an active coagulation disorder. In late 1998,
we initiated an international, multi-center, open-label, dose-ranging Phase II
study of rNAPc2 for the prevention of DVT in patients undergoing unilateral knee
arthroplasty, an orthopedic surgical procedure where DVT is commonly observed.
In late 1999, we began an additional Phase IIa multi-center, double-blind,
placebo-controlled dose escalation study of rNAPc2 in patients undergoing
elective PTCA.
Another member of the NAP family of anticoagulants, rNAP5, is poised to
begin a Phase I trial pending the establishment of a partnership arrangement or
corporate collaboration for this program. This anticoagulant protein is a direct
inhibitor of Factor Xa, in contrast to rNAPc2 that principally inhibits Factor
VIIa/Tissue Factor. We hope to be able to use rNAPc2 and rNAP5 to prevent and
treat the wide range of clinical disorders involving thrombosis such as DVT, PE,
MI and UA. In several animal models of thrombosis, both rNAPc2 and rNAP5 have
been shown to have significant advantages over both UFH and LMWH, the leading
injectable anticoagulants currently in clinical use. Current and future clinical
trials of these two new anticoagulant agents will determine if these advantages
can be extended to man.
-14-
ORAL ANTICOAGULANTS. We are focusing on the development of synthetic
inhibitors of coagulation proteases as a potential new generation of
anticoagulants that can be taken in pill form. Our scientists have identified
specific thrombin inhibitors in this program, including compounds that exhibit
oral bioavailability in canine models. Research activities are focused on the
continued refinement of these compounds for selection of a clinical candidate by
our long-term partner Schering-Plough. See "- Strategic Alliances."
UK-279,276. Our partner Pfizer is developing UK-279,276 (previously
designated as rNIF), a protein that is a highly specific antagonist of
neutrophil activation, adhesion and transmigration into tissue. As with the NAP
protein, our scientists originally discovered UK-279,276 from the hookworm
parasite. UK-279,276 interacts specifically with a key cellular adhesion
receptor (integrin) on the surface of neutrophils known as CD11b/CD18 (Mac-1)
and blocks the adhesion of neutrophils to the endothelium, thereby inhibiting
the first step in the inflammatory response. UK-279,276 has been shown to
inhibit inflammatory responses in several animal models, including the
significant reduction of infarct size or damage to the brain following focal
ischemia in a rodent model of ischemic stroke. We believe that UK-279,276 is the
first identified, naturally-occurring, non-antibody antagonist of CD11b/CD18
that may have application as an acute anti-inflammatory drug with safety and
efficacy advantages over current clinical therapies and other investigational
agents. In February 1997, following extensive preclinical evaluation, we entered
into an exclusive license and development agreement with Pfizer to develop
UK-279,276 as a therapy for ischemic stroke. Pfizer completed Phase I clinical
testing of UK-279,276 in normal volunteers and, based on the favorable
pharmacokinetic and safety profile defined in this trial, UK-279,276 was
advanced to a Phase IIa dose-ranging trial in stroke patients. The primary
objective of this Phase IIa trial, which completed patient enrollment in late
1999, was to determine the pharmacokinetic and safety profile of UK-279,276 in
stroke patients in preparation for future clinical studies. Phase II trials, in
which the primary endpoint will be the effectiveness of UK-279,276 in improving
the outcome of stroke patients, are planned to begin in the second half of 2000,
with the potential for accelerated development. See "- Strategic Alliances."
CANCER PROGRAMS
UPA PROTEASE INHIBITORS. We are using our combinatorial and medicinal
chemistry technologies to discover and develop inhibitors of the serine protease
uPA as a potential new generation of injectable and oral anti-cancer agents. We
have identified lead compounds that inhibit uPA and are selective against
related proteases, including tPA. Selective lead inhibitors have been
demonstrated to effectively inhibit angiogenesis and tumor growth in a commonly
used experimental model (CAM assay) and in immuno-compromised nude mouse models
of human solid tumor cancer. We expect to continue lead optimization and to
expand testing of selected inhibitors in animal models of solid tumor growth and
metastasis as we move toward the selection of a clinical development compound.
-15-
PAI-1 ANTAGONISTS. We are using the information derived from the
three-dimensional structure of PAI-1, in parallel with medicinal chemistry
approaches, to identify specific small molecule lead antagonists of this serpin
inhibitor. To date, compounds have been identified which bind to PAI-1 and
antagonize the inhibition of tPA and uPA IN VITRO. Further optimization of these
compounds is ongoing for eventual testing on relevant models of solid tumor
growth and metastasis.
CANCER PROTEASES. Through the use of molecular gene cloning technology,
we have identified several membrane-bound proteases from cell lines derived from
human tumors and normal tissues. Recombinant versions of several proteases were
screened against our synthetic combinatorial libraries of protease inhibitors,
from which several potent sub-nanomolar compounds were identified. In addition,
the production of monoclonal antibodies to several proteases is in progress.
These lead inhibitors, and eventually monoclonal antibodies, will be used in
animal models of solid tumor cancer to determine the role of the particular
protease in tumor growth and progression. It is expected that this program will
continue to investigate the biological role of other protease targets in solid
tumor growth, angiogenesis and metastasis, which we hope will form the basis of
a new technology platform derived from our continuing interest in the role of
proteases in disease.
OTHER DRUG PROGRAMS
HEPATITIS C PROTEASE INHIBITORS. We are engaged in the discovery of
inhibitors of the enzymatic function of a viral serine protease, NS3, thought to
be a crucial component required for replication of the hepatitis C virus. In
June 1997, we entered into a strategic alliance with Schering-Plough to
collaborate on the development of treatments for chronic hepatitis C infections.
This program has identified compounds with NS3 inhibitory activity which are now
the focus of optimization and testing in relevant cell-based systems. See "-
Strategic Alliances."
FALCIPAIN PROTEASE INHIBITORS. We are using our expertise in the area
of novel protease inhibitor development in a new program directed at inhibitors
of the cysteine protease falcipain, which has been implicated in the survival of
the malaria-causing parasite. In September 1999, we were awarded a government
grant from the National Institute for Allergy and Infectious Disease in the
amount of $599,000 to fund this program. This early-stage program is utilizing
the proprietary combinatorial chemistry technology developed for rapidly
identifying lead inhibitors of cysteine and serine protease inhibitors. Lead
inhibitors of falcipain have been identified using the isolated enzyme IN VITRO.
These lead inhibitors have also been demonstrated to inhibit parasite
development in a culture system using human red blood cells. We are currently in
the process of optimizing these lead compounds, after which we will begin
testing in animal models of malaria infection.
INTEGRATED TECHNOLOGY PLATFORMS
MEDICINAL CHEMISTRY. Corvas scientists have extensive knowledge and
practical experience in computer-aided drug design and have developed novel,
proprietary software to expedite the design of synthetic drug candidates. Using
computer-aided molecular modeling techniques, along with X-ray crystal
structures of native proteases and protease inhibitor complexes, our scientists
have gained valuable insights regarding the unique features of each of our
specific protease and other molecular targets. This information is used to both
design novel inhibitors and to optimize lead compounds. By systematic iterative
synthesis, biological evaluation and modeling, these scientists have developed a
comprehensive database correlating biological activity of candidate drugs with
their structures.
-16-
Our medicinal chemistry expertise is essential to the development of
synthetic pharmaceuticals and is supported and complemented by capabilities in
protein engineering, biochemistry, immunology, monoclonal antibody technology,
analytical chemistry, molecular modeling and IN VITRO and IN VIVO biological
testing. We have built a team of experienced medicinal chemists who have a broad
range of experience in critical areas of pharmaceutical chemistry. Specific
areas of expertise within this group include synthetic, peptide, peptidomimetic,
combinatorial, analytical and small-scale process chemistry. Novel and
proprietary technologies that we have developed, such as the development of
proprietary combinatorial chemistry approaches, may help to speed the process of
drug discovery.
Corvas scientists are currently combining our chemistry expertise with
proprietary combinatorial chemistry strategies to create novel methods of
producing large synthetic libraries of protease inhibitors with a variety of
mechanisms of action. We expect that such methods will improve the speed of lead
identification and optimization efforts, and enable us to rapidly expand our
drug candidate portfolio to include new target proteases, in addition to those
protease targets already part of the Corvas portfolio, such as the coagulation
proteases, uPA, the hepatitis C viral protease and the malaria protease
falcipain. Additionally, our scientists have applied their expertise in
chemistry to non-protease targets such as PAI-1 antagonists, which further
expands the universe of targets that can be considered.
NOVEL BIOLOGICS DISCOVERY. Natural products have been a source of new
drugs for many years. Advances in molecular biology permit the search for, and
identification of, new biological entities in a variety of sources when
appropriate analytical assays exist. Corvas scientists have examined
blood-feeding parasites as a source of biologically-active agents which can
serve as mechanistic probes and potential drug candidates. Using specialized
assays of coagulation proteases and white blood cell function, our scientists
have discovered natural protein molecules that inhibit certain blood coagulation
proteases (NAPs) and certain white blood cell functions (NIF/UK-279,276).
Techniques used to discover these proteins include classical molecular
fractionation and purification, as well as gene cloning using specialized
expression cloning methods developed by Corvas scientists. The study of the
structure and function of molecules evolved by nature to perform specialized
biochemical functions often yields novel insights into molecular mechanisms.
Such studies have provided us with competitive advantages, which are being
applied in our synthetic molecule drug discovery programs. We anticipate using
our biological discovery expertise to identify molecules that act on new drug
discovery targets and to identify novel targets for future discovery programs as
well.
STRATEGIC ALLIANCES
As part of our strategy for the research, development and
commercialization of our products, we have entered into various arrangements
with corporate partners, licensors, licensees and others, and expect to enter
into additional alliances in the future.
-17-
RELATIONSHIPS WITH SCHERING-PLOUGH. In December 1994, we entered into a
strategic alliance agreement with Schering-Plough to collaborate on the
discovery and commercialization of oral thrombin inhibitor drugs for the
prevention and treatment of chronic cardiovascular disorders. Under the terms of
the initial agreement, Schering-Plough compensated us for certain costs of
research and preclinical development of thrombin inhibitors over a two-year
period that ended December 31, 1996. Schering-Plough assumed responsibility for
certain preclinical development, clinical trials and regulatory activities, and
received exclusive worldwide manufacturing and marketing rights for any
resulting thrombin inhibitors. In January 1997, Schering-Plough selected a
clinical development candidate, and paid us a $3,000,000 milestone payment. In
June 1998, Schering-Plough began a Phase I clinical trial of an oral thrombin
inhibitor, which triggered a $1,000,000 milestone payment to us. In August 1998,
both companies agreed to terminate the oral thrombin inhibitor collaboration,
which did not affect the other two ongoing collaborations with Schering-Plough.
In conjunction with the December 1994 agreement for oral thrombin
inhibitors, Schering-Plough acquired an exclusive option to expand our alliance
to include Factor Xa inhibitors. In December 1996, Schering-Plough exercised
this option and agreed to compensate us for certain costs of research and
preclinical development of Factor Xa inhibitors over a two-year period that
originally ended December 31, 1998. In December 1998, Schering-Plough extended
the funding of this program through September 1999 and expanded the scope of the
program to encompass the development of inhibitors of thrombosis, both Factor Xa
and thrombin, using a different design approach than was used in the terminated
program. In September 1999 and again in December 1999, Schering-Plough extended
the oral anticoagulant program, which is presently funded through December 2000.
Schering-Plough, which is responsible for preclinical development, all clinical
trials and regulatory activities, has exclusive worldwide marketing rights for
any resulting inhibitors. We retained certain manufacturing rights and may in
the future receive milestone payments and royalties on sales of drugs resulting
from this alliance.
Upon execution of the initial agreement in 1994, Schering-Plough
purchased 1,000,000 shares of Series A convertible preferred stock of Corvas,
which resulted in net proceeds of $4,864,000. Upon exercise of the Factor Xa
option in 1996, Schering-Plough purchased 250,000 shares of our Series B
convertible preferred stock, which resulted in net proceeds of $2,000,000. In
February 2000, both series of preferred stock converted into 1,250,000 shares of
common stock. Schering-Plough owns approximately 5.9% of our outstanding
securities. Revenue of $7,000,000, $5,000,000 and $4,000,000 was recognized
under both of these agreements in 1997, 1998 and 1999, respectively, and it is
anticipated that $3,000,000 will be recognized in 2000. Through the end of 1999,
we have received a total of $32,000,000 from Schering-Plough as a result of
these programs. If all remaining milestones are met, we could receive an
additional $31,500,000 in milestone payments and research funding, plus
royalties on any sales of commercialized products.
In June 1997, we entered into an additional agreement with
Schering-Plough which covers the design and development of oral inhibitors of a
key protease believed to be necessary for hepatitis C virus replication. Under
the terms of this agreement, Schering-Plough received an exclusive worldwide
license for products resulting from this collaboration and is responsible for
all development, manufacturing and marketing of any resultant products. We
received a license fee of $250,000 in 1997 and, in addition, have recognized
revenue from collaborative agreements of $919,000 in 1997 and $1,575,000 in each
of 1998 and 1999. The initial term of the research program was one year;
Schering-Plough has exercised both of its options to extend funding through May
2000. We may also receive milestone payments, as well as royalty payments on
product sales, if products are successfully commercialized from this agreement.
-18-
RELATIONSHIP WITH PFIZER
In October 1995, we entered into a research and option agreement of up
to eighteen months with Pfizer to collaborate on the development of rNIF, now
referred to by Pfizer as UK-279,276. In February 1997, Pfizer exercised its
option to enter into a license and development agreement and Pfizer compensated
us for certain costs of research and preclinical development of UK-279,276 over
a two-year period that ended March 31, 1999. Pfizer holds an exclusive,
worldwide license to further develop, manufacture and market UK-279,276 as a
therapeutic agent and has the right to terminate the agreement at any time upon
30 days written notice. Pfizer is also responsible for funding all further
development of UK-279,276. In February 1998, Pfizer began a Phase I clinical
trial for UK-279,276, which triggered a $1,000,000 milestone payment to us.
Patient enrollment has recently been completed on a Phase II trial of UK-279,276
that Pfizer initiated in December 1998 in patients suffering from ischemic
stroke. If products are successfully commercialized from this agreement, we will
also receive milestone payments and royalties on product sales. Through the end
of 1999, we have received $4,359,000 from Pfizer under this alliance. If all
stroke-related milestones on this program are met, we could receive an
additional $27,000,000 in milestone payments plus royalties on any sales of
commercialized products.
RELATIONSHIP WITH JOHNSON & JOHNSON COMPANIES
In November 1998, we entered into license agreements with two
affiliates of Johnson & Johnson, Ortho-Clinical Diagnostics Inc. and LifeScan,
Inc. These agreements cover recombinant tissue factor, which is used in
diagnostic tests to determine the blood clotting ability of patients, and
supercede earlier agreements entered in June 1992. In addition to transferring
our manufacturing activities to these affiliates of Johnson & Johnson, certain
specialized equipment was also sold in 1998. The new agreements continue to
provide for royalties to be paid based on unit sales of tissue factor.
RESEARCH COLLABORATIONS AND LICENSES
We have also established collaborations with scientists at a number of
leading North American and European academic and clinical research centers to
further our technology and product development objectives. Generally, these
collaborations give us a license to, or the option to license, certain
technology, patent rights or materials. These agreements may require us to fund
research or to pay license fees or milestone payments and, upon commercial sale
of certain products, royalties. We also have several contractual arrangements
with scientific advisors and collaborators for which we compensate these
individuals or an affiliated entity.
-19-
PATENTS AND PROPRIETARY RIGHTS
Our success depends in part on our ability to obtain patent protection
for our products, both in the U.S. and other countries. The patent position of
biotechnology and pharmaceutical companies is highly uncertain and involves
complex legal and factual questions. There is also uncertainty as to the breadth
of claims that will be allowed in biotechnology patents. We intend to file
applications as appropriate for patents covering both our products and
processes. As of March 15, 2000, we own 51 U.S. patents and have received
Notices of Allowance for at least seven U.S. patent applications that have not
yet issued as patents. We have filed, or hold licenses to, approximately 31
additional patent applications that currently are pending in the U.S. Patent and
Trademark Office, or USPTO. We have filed foreign counterparts to certain of our
issued patents and patent applications in many countries. Generally, it is our
policy to file foreign counterparts in countries with significant pharmaceutical
markets. Some of these foreign counterparts have issued as patents or have been
indicated as allowed. Corporate partners and others may have certain rights to
patents owned by us under applicable strategic alliance and other agreements.
Patents may not issue from any of our owned or licensed patent applications, and
the breadth or scope of protection allowed under any issued patents may not
provide adequate protection. In addition, any patents that we own or have
licensed may be challenged, invalidated or circumvented, and any rights granted
to us may not provide adequate protection.
In addition to patents, we rely on trade secrets and proprietary
know-how, which we seek to protect, in part, through appropriate
confidentiality, proprietary information and invention agreements with our
current and prospective collaborative partners, employees, scientific advisors
and consultants. These agreements may be breached and we may not have adequate
remedies for any breach. Our trade secrets may otherwise become known or be
independently discovered by competitors.
Some of our research, including our new malaria program, has been
funded in part by the U.S. Government's SBIR program or by other government
funding. As a result of this government funding, the government will have rights
in any technology, including inventions, developed with the funding. These
rights include the grant of a non-exclusive, paid-up, worldwide license to such
inventions for any governmental purpose. In addition, the government has the
right to require us to grant an exclusive license to any of these inventions to
a third party if the government determines that (i) adequate steps have not been
taken to commercialize such inventions, (ii) the license is necessary to meet
public health or safety needs or (iii) the license is necessary to meet
requirements for public use under federal regulations. Federal law requires any
licensor of an invention that was partially funded by federal grants to obtain a
covenant from its exclusive licensee to manufacture any products using the
invention in the U.S. In addition, our licenses may also relate to technology
developed with federal funding and, therefore, may also be subject to rights
held by the government.
-20-
GOVERNMENT REGULATION
Alone or through our collaborators, we intend to market our product
candidates in all jurisdictions where we receive the required regulatory
approvals and where we expect such marketing would be commercially successful.
The production and marketing of our products and our ongoing research and
development activities are subject to regulation by numerous governmental
authorities in the U.S. and other countries. Any drug that we develop must
undergo rigorous preclinical and clinical testing and an extensive regulatory
clearance process mandated by the U.S. Food and Drug Administration, or FDA,
and/or applicable foreign authorities before it can be marketed. Various federal
and, in some cases, state statutes and regulations also govern or influence the
manufacturing, safety, labeling, storage, marketing and recordkeeping of such
products. These processes can take a number of years and require the expenditure
of substantial resources. Any failure by us or our collaborators or licensees to
obtain, or any delay in obtaining, regulatory clearances could adversely affect
the marketing of any products we develop and our ability to receive product or
royalty revenue.
The activities required before a drug may be marketed in the U.S. begin
with preclinical testing. Preclinical tests include laboratory evaluation of
product chemistry and animal studies to assess the potential safety and efficacy
of the product and its formulations. The results of these studies must be
submitted to the FDA as part of an Investigational New Drug Application, or IND,
which must be reviewed and become effective pursuant to FDA regulations before
proposed clinical testing in the U.S. can begin. Typically, clinical testing
involves a three-phase process. In Phase I, clinical trials are conducted with a
small number of subjects to determine the early safety profile and the pattern
of drug distribution and metabolism. In Phase II, clinical trials are conducted
with groups of patients afflicted with a specified disease in order to determine
preliminary efficacy, optimal dosages and expanded evidence of safety. In Phase
III, large scale, multi-center, comparative clinical trials are conducted with
patients afflicted with a target disease in order to provide enough data for the
statistical proof of efficacy and safety required by the FDA and others. The
results of the preclinical and clinical testing are then submitted to the FDA,
for a drug in the form of a New Drug Application, or NDA, or for a biological
product in the form of a Biology License Application, or BLA, for approval to
begin commercial sales. In responding to an NDA or BLA, the FDA may grant
marketing clearance, request additional information or deny the application if
it determines that the application does not demonstrate, to the satisfaction of
the FDA, that the product is safe and effective for its labeled indications. For
approved products, the FDA requires that adverse effects be reported to the FDA
and may also require post-marketing testing to monitor for adverse effects,
which can involve significant expense.
Among the conditions for NDA or BLA clearance is the requirement that
the prospective manufacturer's quality control and manufacturing procedures
conform on an ongoing basis with Good Manufacturing Practices, or GMPs. In
complying with GMPs, manufacturers must continue to expend time, money and
effort in the area of production and quality control to ensure full technical
compliance. Manufacturing facilities are subject to periodic inspections by the
FDA. Noncompliance may result in the withdrawal of previously granted clearances
and/or the imposition of other regulatory enforcement sanctions, including civil
penalties, recall, injunction or seizure of products, refusal to grant marketing
approval or to allow the non-compliant company to enter into government
contracts, and criminal prosecution.
-21-
We are also subject to regulation by the Food and Drug branch of the
California Department of Health Services, or FDB, and, prior to marketing any of
our products manufactured in California, we are required to secure a drug
manufacturing license from the FDB. Such licenses are issued after an FDB
inspection of manufacturing facilities, and are reissued on an annual basis
after re-inspection by the FDB.
Additionally, we are subject to various federal, state and local laws,
regulations and recommendations relating to safe working conditions, laboratory
and manufacturing practices, the experimental use of animals and the use,
storage, discharge and disposal of hazardous or potentially hazardous substances
and radioactive compounds and infectious disease agents, used in connection with
our research. We cannot predict the extent of government regulation that might
result from any legislation or administrative action.
COMPETITION
Due to the high incidence of cardiovascular diseases, cancer, viral
infections such as hepatitis C, and parasitic diseases such as malaria, most, if
not all, of the major pharmaceutical companies have significant research and
product development programs in these areas. We expect to encounter significant
competition both in the U.S. and in foreign markets for each of the drugs we
seek to develop. Several existing products have well-established market
positions and there are a number of new products in advanced clinical
development. Our competitors include fully-integrated pharmaceutical and
biotechnology companies both in the U.S. and in foreign markets which have
expertise in research and development, manufacturing processes, testing,
obtaining regulatory clearances and marketing, and may have financial and other
resources significantly greater than we do. Smaller companies may also prove to
be significant competitors. Furthermore, academic institutions, U.S. and foreign
government agencies and other public and private research organizations conduct
research relating to diseases we target, and may develop products for the
treatment of these diseases, that may compete directly with any we develop.
These companies and institutions also compete with us in recruiting and
retaining highly qualified scientific personnel.
Our competition will be partially determined by the potential
indications that we develop and are ultimately cleared for marketing by
regulatory authorities, by the timing of any clearances and market introductions
and by whether any currently available drugs, or drugs under development by
others, are effective in the same indications. Accordingly, the relative speed
with which we can develop products, complete the clinical trials and clearance
processes, and supply commercial quantities of the products to the market is
expected to be an important competitive factor. We expect that competition among
products approved for sale will be based, among other things, on product
efficacy, safety, reliability, availability, price and patent position.
RISK FACTORS
INVESTMENT IN OUR SHARES INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD
CONSIDER THE FOLLOWING DISCUSSION OF RISKS AS WELL AS OTHER INFORMATION IN THIS
REPORT BEFORE PURCHASING ANY OF OUR SHARES. IF ANY OF THE EVENTS OR
CIRCUMSTANCES DESCRIBED IN THE FOLLOWING RISKS ACTUALLY OCCUR, OUR BUSINESS,
FINANCIAL CONDITION, OR RESULTS OF OPERATIONS COULD BE MATERIALLY ADVERSELY
AFFECTED.
-22-
WE STILL ARE AT AN EARLY STAGE OF DEVELOPMENT AND WE DO NOT HAVE, AND MAY NEVER
DEVELOP, ANY COMMERCIAL DRUGS OR OTHER PRODUCTS GENERATING REVENUES.
We are at an early stage of development as a biotechnology company, and
we do not yet have any commercial products. We may never succeed in developing
commercial drugs. Our existing drug candidates will require significant
additional development, clinical trials, regulatory clearances and additional
investment before they can be marketed for sale. These candidates may fail
during the clinical trial process. We do not expect to be able to market any of
our existing drug candidates for a number of years, if at all. Our product
development efforts may not lead to commercial drugs, either because the drug
candidates fail to be effective in clinical trials or because we have inadequate
financial or other resources to pursue the program through the clinical trial
process.
WE HAVE A HISTORY OF OPERATING LOSSES THAT WE EXPECT TO CONTINUE FOR THE
FORESEEABLE FUTURE AND WE MAY NEVER BECOME PROFITABLE.
We have experienced significant operating losses since our inception in
1987. At December 31, 1999, we had an accumulated deficit of approximately
$90,870,000. We expect that we will continue to incur substantial additional
operating losses over the next several years as we pursue our clinical trial and
research and development efforts. To become profitable, we, either alone or with
others, must successfully develop, manufacture and market our current drug
candidates, as well as continue to identify, develop, manufacture and market new
drug candidates, all of which will require regulatory approval and substantial
additional funding.
WE WILL CONTINUE TO NEED ADDITIONAL FINANCING BECAUSE OUR DEVELOPMENT AND
CLINICAL TRIAL EXPENSES EXCEED OUR REVENUES, AND WE MAY NOT BE ABLE TO OBTAIN
FINANCING ON ACCEPTABLE TERMS.
Our operations have consumed substantial amounts of cash since
inception. Our sources of revenue are limited to research funding, license fees
and milestone payments from our corporate collaborators. During 1999, our
expenses exceeded our revenues by $13,017,000. We expect that we will continue
to spend substantial additional amounts on research and development, including
amounts spent on our clinical trials and to manufacture clinical supplies of our
drug candidates. We are seeking to expand into new drug programs to diversify
our pipeline of potential drugs. These new programs require additional cash
investments that are not presently funded through collaborations. Thus, we
expect negative cash flows from operations to continue in the foreseeable future
and we also expect that we will continue to seek additional opportunities to
raise capital.
We will need to raise capital through collaborative arrangements or
through private or public financings. During 1999, we raised gross proceeds of
$15,000,000 through the private sale of 5.5% convertible senior subordinated
notes and the simultaneous sale of common stock. We will continue to seek
opportunities to raise additional capital when available on favorable terms. If
we raise additional funds by selling equity securities, the share ownership of
our existing investors would be diluted or the new equity purchasers could
obtain terms that are better than those of our existing investors. Because of
the risks involved in investing in early-stage biotechnology companies and the
limited number of financing sources making new investments in the biotechnology
industry, we may have difficulties raising additional capital in a timely manner
and on acceptable terms. If we are unable to raise additional capital, we may
have to significantly delay, scale back or discontinue one or more of our drug
discovery programs, clinical trials or other aspects of our operations. We also
could be forced to seek collaborative partners for programs at an earlier stage
than would be desirable to maximize the rights to future product candidates
retained by Corvas.
-23-
WE RELY ON OUR COLLABORATIVE PARTNERS TO FUND PROGRAMS AND CONDUCT CLINICAL
TRIALS. IF WE CANNOT MAINTAIN OUR CURRENT RELATIONSHIPS OR ENTER INTO NEW ONES,
WE MAY NEVER DEVELOP OR COMMERCIALIZE DRUGS.
We rely on certain established pharmaceutical companies to fund a
portion of our research and development expenses. We have collaborative
agreements with Pfizer for the development of UK-279,276 (previously designated
as rNIF), an anti-inflammatory drug that we developed, and with Schering-Plough
for the discovery and commercialization of orally-active inhibitors of (i)
thrombosis (Factor Xa and thrombin) for the prevention and treatment of chronic
cardiovascular disorders and (ii) a key protease associated with hepatitis C
virus replication. As a result, we depend on Pfizer and Schering-Plough for
funding these programs and for the clinical testing and regulatory compliance of
any drug candidates developed through these collaborations. We also will depend
on them to launch and commercially market any drugs cleared by the FDA or
foreign regulatory agencies.
We cannot control the amount and timing of resources dedicated by our
collaborators toward the advancement of our drug programs. In addition, we face
the following risks.
o That our collaborator's interests will no longer coincide with
our interests such that our drug programs will not be
advanced.
o That our collaborators will terminate a program, delay a
clinical trial, underfund a clinical trial program, stop a
clinical trial and abandon a drug candidate, repeat or conduct
new clinical trials or require a new formulation of a drug
candidate for clinical testing.
o That our collaborators will develop, independently or with
third parties, products that could compete with our future
products.
WE ARE ATTEMPTING TO ENTER INTO A COLLABORATIVE AGREEMENT FOR OUR NAP DRUG
PROGRAM. WITHOUT A CORPORATE PARTNER, WE MAY NOT BE ABLE TO ADVANCE RNAPC2 OR
RNAP5.
We are in the process of seeking an appropriate corporate partner for
our proprietary drug program that includes rNAPc2 and rNAP5. The process of
partnering drug programs is lengthy and is subject to risk and uncertainty. We
may not be able to obtain any partner on acceptable terms or within a reasonable
period of time, and we may not find a partner willing to accept only selected
markets.
BECAUSE WE MUST OBTAIN REGULATORY CLEARANCE TO MARKET OUR PRODUCTS IN THE U.S.
AND FOREIGN JURISDICTIONS, WE CANNOT PREDICT WHETHER OR WHEN WE WILL BE
PERMITTED TO COMMERCIALIZE OUR DRUGS.
We must obtain regulatory clearance before we can market or sell our
future drug products, if any reach that stage. In the U.S., we must obtain FDA
clearance for each drug that we intend to commercialize. The FDA clearance
process is typically lengthy and expensive, and is never guaranteed. Drug
products that are distributed abroad are also subject to foreign government
regulation. Since our drug products are in the early development stage, none of
our drug products has received regulatory clearance to be commercially marketed
and sold. If we fail to obtain regulatory clearance, we will be unable to market
and sell any future drugs we develop, and therefore may never be profitable.
-24-
TO OBTAIN REGULATORY CLEARANCE TO MARKET OUR PRODUCTS, COSTLY AND LENGTHY
CLINICAL TRIALS THAT ARE HIGHLY UNCERTAIN ARE REQUIRED. WE MAY NEVER BE
PERMITTED TO COMMERCIALIZE ANY DRUGS WE MAY DEVELOP.
As part of the FDA clearance process, we must conduct, at our own
expense or our partners' expense, preclinical studies on animals and clinical
trials on humans for each drug candidate. The number of preclinical studies and
clinical trials that the FDA requires varies depending on the drug product, the
disease or condition that the drug is being developed to address, and
regulations applicable to any particular drug. We may need to perform multiple
preclinical studies using various doses and formulations before we can begin
clinical trials, which could result in delays in our ability to market any of
our drug products. Furthermore, even if we obtain favorable results in
preclinical studies on animals, the results in humans may be different.
After we have conducted preclinical studies in animals, we must
demonstrate that our drug products are safe and effective for use on the
targeted human patients in order to receive regulatory clearance for commercial
sale. Results that are adverse or inconclusive will stop us from filing for
regulatory clearance of our products. There are many factors that can cause our
clinical trials to be delayed or terminated. These factors include the risk of
slow patient enrollment, lack of sufficient supplies of the drug candidate,
adverse medical events or side effects in treated patients, longer treatment
time required to demonstrate the safe and effective use of the drug and lack of
effectiveness of the drug candidate being used.
In addition, our clinical trials for UK-279,276 (previously designated
as rNIF) are being conducted by Pfizer and we rely on our contractual rights to
access data that they collect. We depend on Pfizer for the data. Pfizer may not
continue the clinical trial process, and the FDA or any foreign regulators may
not clear UK-279,276 for marketing.
OUR COMPETITORS MAY DEVELOP AND MARKET DRUGS THAT ARE LESS EXPENSIVE AND MORE
EFFECTIVE, WHICH MAY DIMINISH OR ELIMINATE THE COMMERCIAL SUCCESS OF ANY DRUGS
WE MAY COMMERCIALIZE.
The biotechnology market is highly competitive. Almost all of the
larger biotechnology companies have developed, or are attempting to develop,
drugs that will compete with drugs we may develop. It is possible that our
competitors will develop and market drugs that are less expensive and more
effective than our future drugs or that will render our drugs obsolete. We
expect that the competition from other biotechnology companies, pharmaceutical
companies, and research and academic institutions will increase. Many of these
competitors have substantially greater financial, technical, research and other
resources than we do. We may not have the financial resources, technical
expertise or marketing, distribution or support capabilities to compete
successfully.
-25-
FAILURE TO RETAIN OUR PRESIDENT AND CHIEF EXECUTIVE OFFICER AND OUR EXECUTIVE
VICE PRESIDENT, RESEARCH AND DEVELOPMENT COULD DECREASE OUR ABILITY TO OBTAIN
FINANCING, CONDUCT CLINICAL TRIALS OR DEVELOP DRUGS.
We depend on our President and Chief Executive Officer, Randall E.
Woods, and our Executive Vice President, Research and Development, George P.
Vlasuk, Ph.D. The loss of either of these individuals may prevent us from
achieving our business objective of commercializing drugs. Both of these
employees has an employment agreement with us, but the agreements provide for
"at-will" employment with no specified term.
WE HAVE LIMITED MANUFACTURING EXPERIENCE AND WE RELY ON THIRD PARTIES TO
MANUFACTURE OUR CLINICAL SUPPLIES.
In order to be successful, our drugs must be manufactured in sufficient
quantities, in compliance with regulatory requirements, and at an acceptable
cost. We have only limited experience in pilot scale manufacturing. For
larger-scale production, as is required for clinical testing, we rely on third
parties to manufacture our drug candidates. If we cannot continue to contract
for large-scale manufacturing capabilities on acceptable terms, we may not be
able to conduct clinical trials. This may result in the delay or preclusion of
submission of drugs for regulatory clearance, which may prevent us from
commercializing drugs and becoming profitable.
IF WE ARE UNABLE TO PROTECT OUR PROPRIETARY TECHNOLOGY, WE MAY NOT BE ABLE TO
COMPETE AS EFFECTIVELY.
Our success depends in part on our ability to obtain and enforce patent
protection for our products, both in the U.S. and other countries, and operate
without infringing the proprietary rights of third parties. The scope and extent
of patent protection for our drug candidates is uncertain and frequently
involves complex legal and factual questions. We cannot predict the breadth of
claims that will be allowed and issued in patents related to biotechnology or
pharmaceutical applications. Once such patents have issued, we cannot predict
how the claims will be construed or enforced. In addition, statutory differences
between countries may limit the protection we can obtain on some of our
inventions outside of the U.S. For example, methods of treating humans are not
patentable in many countries outside of the U.S. We rely on patent and other
intellectual property protection to prevent our competitors from manufacturing
and marketing our drug candidates. Our patents may not be enforceable and they
may not afford us protection against competitors, especially since there is a
lengthy lead time between when a patent application is filed and when it is
actually published. Because of this, we may infringe on intellectual property
rights of others without being aware of the infringement. If a patent holder
believes that our drug candidate infringes on their patent, they may sue us even
if we have received patent protection for our technology. If another party
claims we are infringing on their technology, we could face a number of issues,
including the following.
o Defending a lawsuit, which is very expensive and time
consuming.
o Paying a large sum for damages if we are found to be
infringing.
o Being prohibited from selling or licensing our drugs or drug
candidates until we obtain a license from the patent holder,
who may refuse to grant us a license or will only agree to do
so on unfavorable terms. Even if we are granted a license, we
may have to pay substantial royalties or grant cross-licenses
to our patents.
o Redesigning our drug so it does not infringe on the patent
holder's technology if we are unable to obtain a license. This
may not be possible and even if possible, it would require
substantial additional capital and would delay
commercialization.
-26-
The coverage claimed in a patent application can be significantly
narrowed before a patent is issued, either in the U.S. or abroad. We do not know
whether any of our pending or future patent applications will result in the
issuance of patents. To the extent patents have been issued or will be issued,
we do not know whether these patents will be subjected to further proceedings
limiting their scope, will provide significant proprietary protection or
competitive advantage, or will be circumvented or invalidated. Furthermore,
patents already issued to us, or patents which may issue on our pending
applications, may become subject to dispute, including interference proceedings
in the U.S. to determine priority of invention or opposition proceedings in
foreign countries contesting the validity of issued patents.
We also rely on trade secrets and proprietary know-how to develop and
maintain our competitive position. While we believe that we have protected our
trade secrets, some of our current or former employees, consultants or
scientific advisors, or current or prospective collaborative partners, may
unintentionally or willfully disclose our confidential information to
competitors or use our proprietary technology for their own benefit.
Furthermore, enforcing a claim alleging the infringement of our trade secrets
would be expensive and difficult to prove, making the outcome uncertain. Our
competitors may also independently develop equivalent knowledge, methods and
know-how.
Since we collaborate with third parties on some of our technology,
there is also the risk that disputes may arise as to the rights to technology or
drugs developed in collaboration with other parties.
IF WE BECOME SUBJECT TO PRODUCT LIABILITY CLAIMS, THE DAMAGES MAY EXCEED OUR
INSURANCE.
Since we conduct clinical trials on humans, we face the risk that the
use of our drug candidates will result in adverse effects. Such risks will exist
even for drugs that may be cleared for commercial sale. We have obtained
liability insurance of $10,000,000 for our drug candidates in clinical trials.
We cannot predict all of the possible harms or side effects that may result and,
therefore, the amount of coverage we currently hold may not be adequate to
protect us from any liabilities. We may not have sufficient resources to pay for
any liabilities resulting from a claim beyond the limit of our insurance
coverage.
THE REIMBURSEMENT STATUS OF NEWLY APPROVED HEALTH CARE DRUGS IS UNCERTAIN AND
FAILURE TO OBTAIN ADEQUATE REIMBURSEMENT COULD LIMIT OUR ABILITY TO MARKET ANY
DRUGS WE MAY DEVELOP AND DECREASE OUR ABILITY TO GENERATE REVENUE.
There is significant uncertainty related to the reimbursement of newly
approved health care products, including drugs. Our ability to commercialize our
drugs in both domestic and foreign markets will depend in part on the
reimbursements obtained by third-party payors such as government health
administration authorities, private health insurers, managed care programs and
other organizations. Third-party payors are increasingly attempting to contain
health care costs by limiting both coverage and the level of reimbursement of
new drugs. Cost control initiatives could decrease the price that we, or our
collaborators, would receive for our products and affect our ability to
commercialize any drugs we may develop. If third-parties fail to provide
reimbursement for any drugs we may develop, consumers and doctors may not choose
to use our drugs and we may not realize an acceptable return on our investment
in product development.
WE DO NOT HAVE ANY SALES, MARKETING OR DISTRIBUTION EXPERIENCE.
Since we do not have any marketed products, we have limited experience
in sales, marketing and distribution. To directly market and distribute any
products we may develop, we must build a substantial marketing and sales force
with appropriate technical expertise and supporting distribution capabilities.
Alternatively, we may obtain the assistance of a pharmaceutical company or other
entity with a large distribution system and a large direct sales force. We may
not be able to establish sales, marketing and distribution capabilities of our
own or enter into such arrangements with third parties in a timely manner or on
acceptable terms.
THE GOVERNMENT MAY HAVE RIGHTS TO CERTAIN OF OUR TECHNOLOGY.
In September 1999, we were awarded a government grant from the National
Institute for Allergy and Infectious Disease to support our research related to
the treatment of malaria. As a result of the grant, the government will obtain
rights in the technology, including inventions, developed with their funding. In
addition, the government may require us to grant to a third party an exclusive
license to any inventions resulting from the grant if the government determines
that we have not taken adequate steps to commercialize inventions or for public
health or safety needs.
-27-
OUR OPERATIONS INVOLVE HAZARDOUS MATERIALS, WHICH COULD SUBJECT US TO
SIGNIFICANT LIABILITIES.
Our research and development activities involve the controlled use of
hazardous materials, including chemicals and radioactive and biological
materials. Our operations also produce hazardous waste products. We are subject
to a variety of federal, state and local regulations relating to the use,
handling and disposal of these materials. We generally contract with third
parties for the disposal of such substances, and store our low level radioactive
waste at our facility until the materials are no longer considered radioactive
because there are no facilities permitted to accept such waste in California or
neighboring states. While we believe that we comply with current regulatory
requirements, we cannot eliminate the risk of accidental contamination or injury
from these materials. We may be required to incur substantial costs to comply
with current or future environmental and safety regulations. Any accident or
contamination could result in civil penalties or criminal fines, impact out
facilities and operations, and subject us to significant liabilities.
OUR STOCK HAS BEEN, AND MAY CONTINUE TO BE, EXTREMELY VOLATILE.
The market price of our common stock has been, and likely will continue
to be, extremely volatile. Our stock price could be subject to wide fluctuations
in response to a variety of factors, including the following.
o Changes in the market valuations of biotechnology companies.
o Announcements of technological innovations or new products or
services by us or by our competitors.
o Announcements regarding our clinical trials.
o Developments related to patents or other proprietary rights of
us or others.
o Changes in financial estimates of us by securities analysts.
o Actions by governmental regulatory agencies.
o Announcements by us or our competitors of acquisitions,
strategic relationships, joint ventures or capital
commitments.
o Developments in domestic and international governmental policy
or regulation.
o Additions or departures of our key personnel.
o Sales of our common stock in the open market.
o Other events or factors beyond our control.
OUR STOCKHOLDERS RIGHTS PLAN AND PROVISIONS IN OUR CERTIFICATE OF INCORPORATION,
BYLAWS AND DELAWARE LAW MAY ADVERSELY AFFECT A POTENTIAL TAKEOVER AND COULD
PREVENT A STOCKHOLDER FROM RECEIVING A FAVORABLE PRICE FOR THEIR SHARES.
Our certificate of incorporation provides for a classified board of
directors and includes a provision that requires the approval of holders of at
least 66 2/3% of our voting stock as a condition to a merger or certain other
business transactions with, or proposed by, a holder of 15% or more of our
voting stock. This approval is not required in cases where certain of our
directors approve the transaction or where certain minimum price criteria and
other procedural requirements are met. Our certificate of incorporation also
requires the approval of holders of at least 66 2/3% of our voting stock to
amend or change the provisions mentioned relating to the classified board or the
transaction approval. In addition, our certificate of incorporation authorizes
preferred stock. Our board of directors may issue shares of preferred stock
without stockholder approval and on terms determined by the board of directors.
The classified board, transaction approval and other charter provisions may
discourage certain types of transactions involving an actual or potential change
in our control. These provisions may also discourage certain types of
transactions in which our stockholders might otherwise receive a premium for
their shares over the then-current market prices and may limit our stockholders'
ability to approve transactions that they may deem to be in their best
interests.
-28-
Further, we have distributed a dividend of one right for each
outstanding share of our common stock pursuant to the terms of our rights plan,
or "poison pill." These rights will cause substantial dilution to the ownership
of a person or group that attempts to acquire us on terms not approved by our
board of directors, and may have the effect of deterring hostile takeover
attempts. In addition, our board of directors has the authority to fix the
rights and preferences of, and issue shares of, preferred stock. These rights
may have the effect of delaying or preventing a change in our control without
action by our stockholders.
ISSUANCE OF SHARES UNDER STOCK OPTION PLANS AND OUTSTANDING WARRANTS WILL DILUTE
CURRENT STOCKHOLDERS.
We maintain stock option plans whereby employees, directors and
consultants can acquire shares of Corvas common stock through the exercise of
stock options. In addition, we have outstanding warrants. You will incur
dilution upon exercise of our outstanding options or warrants. Both the number
of certain outstanding warrants and their exercise price are adjusted
semi-annually due to the accretion of interest on our convertible notes.
Therefore you will also incur dilution when the number of warrants outstanding
is adjusted.
HUMAN RESOURCES
As of March 15, 2000, we employed 73 individuals on a full-time basis,
of which 20 hold Ph.D. degrees.
A significant number of our management and professional employees have
had prior experience with pharmaceutical, biotechnology or medical product
companies. We believe that we have been successful in attracting skilled and
experienced scientific personnel; however, competition for such personnel is
intense. None of our employees is covered by a collective bargaining agreement.
All of our employees are covered by confidentiality and arbitration agreements,
and certain of our officers have employment contracts. We believe that our
relationship with employees is good.
ITEM 2. PROPERTIES
Corvas presently occupies approximately 31,300 square feet of
laboratory and office space in San Diego, California. We are seeking to lease
additional laboratory and office space in the near future.
We do not have manufacturing facilities for pilot scale or commercial
production of compounds under development as therapeutic products. We presently
rely on third parties to manufacture our candidate products for clinical
testing.
-29-
For our drug candidates, we will need to expand our quality control and
quality assurance programs to support the manufacture of additional clinical
supplies, as well as any future commercial drugs, if and when cleared for
marketing. We will continue to be dependent on contract manufacturers or
strategic partners for manufacturing. These manufacturers may not be available
or may not meet our requirements for quality, quantity and timeliness. We may
not be able to find substitute manufacturers, if necessary.
ITEM 3. LEGAL PROCEEDINGS
None
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
Corvas common stock began trading on The Nasdaq Stock Market on January
30, 1992 under the symbol "CVAS." Prior to January 30, 1992, there was no public
market for our common stock. The following table sets forth the high and low
sale prices of our common stock as reported by the Nasdaq National Market for
the periods indicated.
HIGH LOW
------ -----
YEAR ENDED DECEMBER 31, 1999
Fourth Quarter $5.00 $2.00
Third Quarter 3.63 2.31
Second Quarter 3.19 1.88
First Quarter 3.28 2.00
YEAR ENDED DECEMBER 31, 1998
Fourth Quarter $3.75 $1.63
Third Quarter 4.38 1.75
Second Quarter 5.81 3.88
First Quarter 5.50 3.25
On March 15, 2000, the last reported sale price of our common stock was
$11.88 per share, and there were approximately 633 holders of record of our
common stock.
-30-
ITEM 6. SELECTED FINANCIAL DATA
The selected data presented below under the captions "Statements of
Operations Data" and "Balance Sheets Data" for, and as of the end of, each of
the years in the five-year period ended December 31, 1999, are derived from the
financial statements of Corvas International, Inc., which financial statements
have been audited by KPMG LLP, independent certified public accountants. The
audited financial statements as of December 31, 1999 and 1998, and for each of
the years in the three-year period ended December 31, 1999, and the independent
auditors' report thereon, are included elsewhere in this report. Along with this
selected financial data, it is important that you read the historical financial
statements and related notes, as well as the "Management's Discussion and
Analysis of Financial Condition and Results of Operations" included elsewhere in
this report.
YEAR ENDED DECEMBER 31,
-------------------------------------------------------------------
(In thousands, except per share amounts)
STATEMENTS OF OPERATIONS DATA: 1999 1998 1997 1996 1995
----------- ----------- ----------- ----------- -----------
REVENUES:
Revenue from collaborative agreements $ 6,088 $ 6,985 $ 5,811 $ 5,480 $ 4,354
License fees and milestones --- 2,795 4,100 400 500
Net product sales --- 44 374 224 406
Royalties 190 145 120 161 142
Research grants 14 --- --- --- ---
----------- ----------- ----------- ----------- -----------
Total revenues 6,292 9,969 10,405 6,265 5,402
----------- ----------- ----------- ----------- -----------
COSTS AND EXPENSES:
Research and development 14,669 15,800 9,705 10,901 9,723
General and administrative 5,320 3,670 4,469 3,181 2,582
Cost of products sold --- 18 194 134 211
----------- ----------- ----------- ----------- -----------
Total costs and expenses 19,989 19,488 14,368 14,216 12,516
----------- ----------- ----------- ----------- -----------
Loss from operations (13,697) (9,519) (3,963) (7,951) (7,114)
Other income, net 901 1,415 1,511 1,248 832
Interest expense (221) --- --- (6) (11)
----------- ----------- ----------- ----------- -----------
680 1,415 1,511 1,242 821
----------- ----------- ----------- ----------- -----------
Net loss and other comprehensive loss $ (13,017) $ (8,104) $ (2,452) $ (6,709) $ (6,293)
=========== =========== =========== =========== ===========
Basic and diluted net loss per share(1) $ (0.82) $ (0.56) $ (0.18) $ (0.52) $ (0.67)
=========== =========== =========== =========== ===========
Shares used in calculation of basic
and diluted net loss per share(1) 15,842 14,460 13,873 12,882 9,374
=========== =========== =========== =========== ===========
DECEMBER 31,
-------------------------------------------------------------------
BALANCE SHEETS DATA: 1999 1998 1997 1996 1995
----------- ----------- ----------- ----------- -----------
Cash, cash equivalents and
short-term debt securities $ 21,511 $ 17,613 $ 26,120 $ 28,596 $ 12,451
Working capital 20,278 16,902 21,133 24,254 7,372
Total assets 23,889 19,912 28,214 30,639 14,462
Accumulated deficit (90,870) (77,853) (69,749) (67,297) (60,588)
Total stockholders' equity 11,275 18,386 22,445 24,347 8,768
- ---------------------
(1) See Note 2 of the Notes to Financial Statements.
-31-
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
THE FOLLOWING DISCUSSION OF OUR FINANCIAL CONDITION AND RESULTS OF OPERATIONS
CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. OUR
ACTUAL RESULTS MAY DIFFER MATERIALLY FROM WHAT IS DISCUSSED IN THE
FORWARD-LOOKING STATEMENTS. FACTORS THAT MIGHT CAUSE SUCH A DIFFERENCE INCLUDE,
BUT ARE NOT LIMITED TO, THOSE DISCUSSED IN OUR ANNUAL REPORT ON FORM 10-K UNDER
THE HEADING "RISK FACTORS."
OVERVIEW
Corvas International is a clinical-stage biopharmaceutical firm engaged
in the design and development of a new generation of therapeutic agents for
cardiovascular, cancer, stroke and other major diseases. Since our inception in
1987, we have not generated significant revenues from product sales and we
currently do not sell any commercial products. We have not been profitable on an
annual basis since inception and we anticipate that we will incur substantial
additional operating losses over the next several years as we progress in our
research and development programs. We expect our sources of revenue, if any, for
the next several years will continue to primarily consist of payments under
collaborative agreements and interest income. Our historical results are not
necessarily indicative of our future results. In addition, we may not
successfully develop, commercialize, manufacture or market any products or
generate sufficient revenues to ever achieve or sustain profitability. At
December 31, 1999, we had an accumulated deficit of $90,870,000.
RESULTS OF OPERATIONS
TOTAL REVENUES. Our total operating revenues in 1999 decreased to
$6,292,000 from $9,969,000 in 1998 and $10,405,000 in 1997. Revenues from
collaborative agreements in 1999, which decreased by $897,000 from the 1998
amount, included (i) $4,000,000 attributable to our strategic alliance agreement
with Schering-Plough to collaborate on the discovery and commercialization of an
oral anticoagulant for chronic thrombosis, (ii) $1,575,000 related to our
collaborative agreement with Schering-Plough for the design and development of
an oral inhibitor of a key protease associated with hepatitis C virus
replication, (iii) $400,000 pursuant to the now-terminated research and
development agreement with Vascular Genomics Inc., or VGI, and (iv) $113,000
attributable to our research and option agreement with Pfizer Inc. to
collaborate on the development of UK-279,276 (previously designated as rNIF). No
license fees and milestones were recognized in 1999, compared to $2,795,000 in
1998. Since we discontinued tissue factor manufacturing in 1998, we had no
product sales in 1999, compared to $44,000 in 1998. We were awarded a Small
Business Innovation Research grant in September 1999 to fund our malaria
research program, which resulted in revenues of $14,000 in 1999.
Revenues from collaborative agreements in 1998 increased by $1,174,000
from 1997 and included (i) $4,000,000 attributable to our strategic alliance
agreement with Schering-Plough covering the discovery and commercialization of
oral anticoagulants for chronic thrombosis, (ii) $1,575,000 related to our
collaborative agreement with Schering-Plough for the design and development of
oral inhibitors of a key protease necessary for hepatitis C virus replication,
(iii) $960,000 pursuant to the research and development agreement with VGI, and
(iv) $450,000 attributable to our research and option agreement with Pfizer to
-32-
collaborate on the development of UK-279,276 (previously designated as rNIF).
License fees and milestones in 1998 decreased $1,305,000 from the 1997 amounts
and were comprised of (i) a $1,000,000 milestone payment received from Pfizer
upon commencement of a Phase I trial of UK-279,276 (previously designated as
rNIF), (ii) a $1,000,000 milestone payment received from Schering-Plough upon
commencement of a Phase I trial of an oral thrombin inhibitor, and (iii) license
fees of $795,000 from the transfer of recombinant tissue factor manufacturing to
two Johnson & Johnson subsidiaries. The $330,000 decrease in product sales
comparing 1998 to 1997 is due to the discontinuation of tissue factor
manufacturing.
RESEARCH AND DEVELOPMENT EXPENSES. Research and development
expenditures, which accounted for 73% of our total costs and expenses in 1999,
81% in 1998 and 68% in 1997, decreased to $14,669,000 in 1999 from $15,800,000
in 1998. This $1,131,000 decrease was due to a lower headcount for most of 1999,
and the termination of the option and related research and development
agreements with VGI. Research and development costs in 1998 increased by
$6,095,000 from the 1997 amounts, primarily due to the VGI program and clinical
development costs for rNAPc2.
GENERAL AND ADMINISTRATIVE EXPENSES. General and administrative
expenses increased to $5,320,000 in 1999 from $3,670,000 in 1998. This
$1,650,000 increase was due to settlement costs associated with the termination
of the VGI program. Comparing 1998 to 1997, general and administrative expenses
decreased to $3,670,000 from $4,469,000, due mainly to reductions in legal,
business development and recruiting costs.
OTHER INCOME. Total other income was $680,000 in 1999, $1,415,000 in
1998 and $1,511,000 in 1997. The largest component each year has been interest
income, which has fluctuated based on varying cash balances available for
investment. In 1999, we had interest income of $901,000 and interest expense of
$221,000. The interest expense related to the 5.5% senior subordinated
convertible notes, in an aggregate principal amount of $10,000,000, that were
issued in 1999 and are due in August 2006. In addition to interest income, the
1998 amount also included $214,000 from the sale of certain equipment and
materials to a Johnson & Johnson subsidiary in connection with the transfer of
tissue factor manufacturing.
Provided that additional capital is available, we expect to continue to
incur significant expenses and operating losses over the next several years as
research and development and clinical trials progress. However, we may not be
able to raise any additional capital.
LIQUIDITY AND CAPITAL RESOURCES
Since our inception, we have financed our operations primarily through
a public offering and private placements of our debt and equity securities,
payments from collaborative agreements, and interest income earned on cash and
investment balances. Our principal sources of liquidity are cash and cash
equivalents, time deposits and debt securities which, net of a restricted time
deposit, totaled $21,290,000 and $17,553,000 as of December 31, 1999 and 1998,
respectively. Cash used in 1999 operations was $11,469,000. Cash used in
investing activities in 1999, including $246,000 to purchase capital equipment,
was $3,280,000. Cash provided by financing activities in 1999 included
$9,873,000 from the sale and issuance of convertible notes, $4,867,000 from the
sale of common stock which occurred simultaneously with the issuance of the
notes, and $279,000 from the issuance of common stock under employee stock
purchase and option plans.
-33-
Subsequent to December 31, 1999, we received $10,650,000 in total net
proceeds from the exercise of warrants held by three groups of institutional
investors.
We invest available cash in accordance with an investment policy set by
our Board of Directors, which has established objectives to preserve principal,
maintain adequate liquidity and maximize income. Our policy provides guidelines
concerning the quality, term and liquidity of investments. We presently invest
our excess cash primarily in government-backed debt instruments and, to a
smaller degree, in debt instruments of corporations with strong credit ratings.
In August 1999, we issued and sold in a private financing 1,300,000
shares of common stock for $2.50 per share and a 5.5% convertible senior
subordinated note, due in August 2006, in an original principal amount of
$6,500,000. Upon maturity, this note will have an accreted value of $9,503,000.
Net proceeds of $6,377,000 were raised through the issuance of this note and net
proceeds of $3,139,000 from the issuance of common stock. Interest on the
outstanding principal amount of this note accretes at 5.5% per annum from August
1999 to August 2006, compounded semi-annually, with interest payable upon
redemption or conversion. In October 1999, we issued and sold in a private
financing 700,000 shares of common stock for $2.50 per share and an additional
5.5% convertible senior subordinated note, also due in August 2006, in an
original principal amount of $3,500,000. Upon maturity, this additional note
will have an accreted value of $5,069,000. Estimated net proceeds of $3,496,000
and $1,728,000, respectively, were raised through the issuance of the second
note and the additional common stock. Interest on the outstanding principal of
the second note accretes at 5.5% per annum from October 1999 to August 2006,
compounded semi-annually, with interest payable upon redemption or conversion.
At our option, the accretion on both notes may be paid in cash or in our common
stock priced at the then-current market price. We have agreed to pay any
applicable withholding taxes that may be required in connection with the
accretion, which are estimated and accrued at 30% of the annual accretion. At
the option of the note holder, the principal of both notes is convertible into
shares of Corvas common stock at $3.25 per share, subject to certain
adjustments. We may call the notes for redemption anytime after August 18, 2002.
We expect that we will continue to incur substantial additional costs
in the foreseeable future due to, among other factors, costs related to ongoing
and planned clinical trials and other research and development activities. Over
the next several years, we expect these costs will result in additional
operating losses and negative cash flows from operations. We are continuing to
pursue additional collaborative relationships, particularly for our NAP program.
We currently believe that our existing resources, projected interest income and
proceeds from the exercise of warrants in early 2000 should be sufficient to
satisfy our anticipated funding requirements for more than 2 years. In the
future, we may also receive additional funds from milestone payments and
royalties on sales of products in connection with our alliances. However, we may
not receive any additional amounts under our existing or any future alliances,
and we may not be successful in raising additional capital through strategic or
other financings or through collaborative relationships. Additionally, our
expected cash requirements may vary materially from those now planned.
-34-
Strategic collaborations that are ongoing with Schering-Plough and
Pfizer provide for payments to us if certain milestones are met. In addition to
future milestones, we may also receive royalties on product sales in connection
with our existing alliances, as well as from any future alliances. If all the
milestones on all of our existing collaborations are met, Corvas could receive a
maximum of $72,144,000 in future milestone payments and research and development
funding over the next several years. Our existing collaborations may not be
successful, we may not receive any future milestones or other payments related
to our collaborative agreements, and our collaborations may not continue (since
the existing agreements are terminable at the option of our collaborators upon
certain events).
Our future capital requirements will depend on many factors, including:
o the scientific progress in, and magnitude of, our drug discovery
programs;
o the scope and results of our preclinical testing and clinical
trials;
o the time and costs involved in obtaining regulatory approvals;
o the costs of filing, prosecuting, maintaining and enforcing patents;
o the progress of competing technology and other market developments;
o our ability to establish and maintain collaborative or licensing
arrangements;
o any changes in our existing collaborative relationships;
o the cost of manufacturing scale-up; and
o the effectiveness of our activities and arrangements, or those of
our collaborative partners, to commercialize our products.
To continue our long-term product development efforts, we must raise
substantial additional funding either through collaborative arrangements or
through public or private financings. Our ability to raise additional funds
through sales of securities depends in part on investors' perceptions of the
biotechnology industry, in general, and of Corvas, in particular. The market for
securities of biotechnology companies, including Corvas, has historically been
highly volatile and, accordingly, additional funding may not be available on
acceptable terms or at all. If additional funds are raised by issuing
securities, our stockholders will experience dilution, which may be substantial.
We may enter into additional collaborative relationships to develop and
commercialize some or all of our current or future technologies or products. We
may not be able to establish such relationships on satisfactory terms, if at
all, and agreements with collaborators may not successfully reduce our funding
requirements. In addition, we have not attempted to establish bank financing
arrangements, and we may not be able to establish such arrangements on
satisfactory terms, if at all. If adequate funds are not available in the
future, we may be required to significantly delay, scale back or discontinue one
or more of our drug discovery programs, clinical trials or other aspects of our
operations. We could also be forced to seek collaborative partners for programs
at an earlier stage than would be desirable to maximize the rights to future
product candidates retained by Corvas.
Our net operating loss carryforwards available to offset future taxable
income at December 31, 1999 were approximately $86,300,000 for federal income
tax reporting purposes, and begin to expire in 2002. The net operating loss
carryforwards for state purposes, which expire five years after generation, are
approximately $45,600,000. We also had unused research and development tax
credits for federal income tax reporting purposes of $4,100,000 at December 31,
1999. In accordance with Internal Revenue Code Section 382, the future
utilization of net operating loss carryforwards and credits may be limited as a
result of defined ownership changes.
-35-
NEW ACCOUNTING STANDARDS
In June 1999, the Financial Accounting Standards Board issued Statement
of Financial Accounting Standards No. 133, "Accounting for Derivative
Instruments and Hedging Activities" (SFAS 133), which was updated by Statement
of Financial Accounting Standards No. 137 (SFAS 137). SFAS 133 and SFAS 137
require companies to recognize all derivatives as either assets or liabilities,
with the instruments measured at fair value. The accounting for changes in fair
value gains and losses depends on the intended use of the derivative and its
resulting designation. SFAS 133 and SFAS 137 become effective for us on January
1, 2001; however we do not believe adoption will have a material impact on our
financial statements.
In December 1999, the Securities and Exchange Commission issued Staff
Accounting Bulletin No. 101, "Revenue Recognition in Financial Statements" (SAB
101), which includes certain revenue recognition issues related to biotechnology
companies. We are currently evaluating the impact of SAB 101 on our reported
results.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We invest our excess cash in short-term, high quality fixed income
investments that are held to maturity. We do not invest in derivative financial
instruments or any other market risk sensitive instruments. See Note 2 of the
Notes to Financial Statements for information about these financial instruments.
Interest income earned on our short-term investment portfolio is affected by
changes in the general level of interest rates. We believe that our interest
rate market risk is limited, and that we are not exposed to significant changes
in fair value because our investments are held to maturity. The fair value of
each investment approximates its amortized cost.
We have assumed that the similar nature of our short-term investments
warrant aggregation for purposes of interest rate sensitivity. The principal
amount of held to maturity investments at December 31, 1999, which mature at
various dates in 2000, is $20,630,000. The related weighted-average interest
rate is 5.8%.
Due to the fixed rate nature of the convertible notes payable that were
issued in 1999, an immediate 10% change in interest rates would not have a
material impact on our financial condition or our results of operations.
Underlying market risk exists related to an increase in our stock price
or an increase in interest rates that may make conversion of the convertible
notes payable into common stock beneficial to the holder. Conversion of the
convertible notes payable would have a dilutive effect on ownership of our
stock.
-36-
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INDEX TO FINANCIAL STATEMENTS
Page
----
Independent Auditors' Report ...................................................................F-1
Balance Sheets as of December 31, 1999 and 1998.................................................F-2
Statements of Operations for the three years ended December 31, 1999............................F-3
Statements of Stockholders' Equity for the three years ended December 31, 1999..................F-4
Statements of Cash Flows for the three years ended December 31, 1999............................F-5
Notes to Financial Statements...................................................................F-6
-37-
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
Information regarding the Directors and Executive Officers of the
Company as of March 15, 2000 is set forth below. Information regarding the
compliance with Section 16 filing requirements will be set forth under the
caption "Compliance with Section 16(a) of the Securities and Exchange Act of
1934" in our 2000 proxy statement and is incorporated by reference into this
report.
EXECUTIVE OFFICERS AND DIRECTORS
The executive officers and directors of the Company, their ages, and
certain other information about them as of March 15, 2000 is set forth below:
NAME AGE POSITION
---- --- --------
Randall E. Woods (1) ............................. 48 President, Chief Executive Officer and
Director
George P. Vlasuk, Ph.D. .......................... 44 Executive Vice President, Research and
Development, Director
Carolyn M. Felzer ................................ 43 Senior Director of Finance, Assistant
Corporate Secretary
M. Blake Ingle, Ph.D. (1) (2) (3)................. 57 Chairman of the Board
J. Stuart Mackintosh (2).......................... 44 Director
Burton E. Sobel, M.D. (3)......................... 62 Director
Michael Sorell, M.D. (2) ......................... 52 Director
Nicole Vitullo (1) (3) ........................... 42 Director
- ------------
(1) Member of Executive Committee
(2) Member of Audit Committee
(3) Member of Compensation and Stock Option Committee
-38-
RANDALL E. WOODS has served as our President and Chief Executive
Officer and as a director of Corvas since May 1996. Prior to joining Corvas, Mr.
Woods served as the President of the U.S. Operations, Boehringer Mannheim
Pharmaceuticals Corporation, or Boehringer, a pharmaceutical company, from March
1994 to March 1996, and was Vice President of Marketing and Sales for Boehringer
from December 1993 to March 1994. From 1973 to December 1993, he served in
various capacities at Eli Lilly and Company, a pharmaceutical company, where he
was most recently responsible for the marketing of hospital products. Mr. Woods
received his M.B.A. from Western Michigan University.
GEORGE P. VLASUK, PH.D. has served as one of our directors since June
1999 and as our Executive Vice President, Research and Development since
September 1996. Previously, Dr. Vlasuk served as Vice President, Biological
Research from January 1995 to September 1996, as Executive Director, Molecular
Pharmacology from July 1993 to January 1995 and as Director, Molecular
Pharmacology from July 1991 to July 1993. Before joining Corvas, he was employed
for six years at Merck Sharp & Dohme Research Laboratories, a pharmaceutical
company, most recently as Associate Director of Hematology Research. Dr. Vlasuk
received his Ph.D. in biochemistry from Kent State University.
CAROLYN M. FELZER has served as our Senior Director of Finance and
Assistant Corporate Secretary since December 1997. Previously, Ms. Felzer served
as the Company's Controller from January 1993 through December 1997 and as our
Accounting Manager from July 1991 through January 1993. Prior to joining Corvas,
Ms. Felzer held various financial positions with private companies since
beginning her career at Peat, Marwick, Mitchell & Co., a professional advisory
firm now known as KPMG LLP. She received a B.S. in accounting from The
Pennsylvania State University and is a Certified Public Accountant.
M. BLAKE INGLE, PH.D. has served as one of our directors since January
1994 and as Chairman of the Board since June 1999. Since 1998, Dr. Ingle has
been a general partner of Inglewood Ventures, a venture capital firm. From March
1993 to his retirement in February 1996 when it was acquired by Schering-Plough,
Dr. Ingle was the President and Chief Executive Officer of Canji, Inc., a
biopharmaceutical company. Prior to that, he was employed in a variety of
capacities with the IMCERA Group, Inc., a healthcare company, consisting of
Mallinckrodt Medical, Mallinckrodt Specialty Chemicals and Pitman Moore, from
1980 to 1993, most recently serving as President and Chief Executive Officer.
Dr. Ingle currently serves on the Boards of Directors of Vical, Inc., Inex
Pharmaceuticals Corp., NewBiotics, Inc. and GeneFormatics Inc., and is the
Chairman of the Board of Trustees at The Burnham Institute.
J. STUART MACKINTOSH has served as one of our directors since February
2000. Since 1985, Mr. Mackintosh has served in various capacities with European
Investors Incorporated, an investment management firm, and is currently Managing
Director and Principal. Before joining European Investors Incorporated, he was
an Assistant Vice President with Bank of Boston.
BURTON E. SOBEL, M.D. has served as one of our directors since February
2000. Since 1994, he has been Physician-in-Chief at Fletcher Allen Health Care
and E.L. Amidon Professor and Chair of the Department of Medicine at The
University of Vermont College of Medicine. Dr. Sobel currently serves on the
Board of Directors of Scios Inc. and has been a consultant to and served on
scientific advisory boards of several pharmaceutical and biotechnology
companies.
-39-
MICHAEL SORELL, M.D. has served as one of our directors since April
1996. Since March 1996, he has been the Managing Partner of MS Capital, LLC, an
advisement firm based in New York. From July 1986 to February 1992, he was
associated with Morgan Stanley & Co., an investment banking firm, in various
capacities, the last being principal. From March 1992 to July 1994, he was a
partner in a joint venture with Essex Investment Management of Boston, an
investment management firm. In August 1994, he rejoined Morgan Stanley as the
emerging growth strategist and principal where he served until February 1996.
Prior to that, he was on the staff of Memorial Sloan-Kettering Cancer Center and
worked in clinical development at Schering-Plough.
NICOLE VITULLO has served as one of our directors since April 1996.
Since April 1999, she has been Managing Director at Domain Associates, L.L.C., a
venture capital management company focused on life sciences. From November 1996
to April 1999, Ms. Vitullo was a Senior Vice President, and from November 1992
to November 1996 was a Vice President, of Rothschild Asset Management Inc.,
which manages International Biotechnology Trust plc and has advised
Biotechnology Investments, Limited. She served as Director of Corporate
Communications at Cephalon, Inc., a neuropharmaceutical company, from July 1991
to November 1992. Prior to that, she was Manager, Healthcare Investments at
Eastman Kodak Company. She also serves on the Boards of Directors of Epimmune
Inc. and Onyx Pharmaceuticals Inc.
ITEM 11. EXECUTIVE COMPENSATION
The information required by this item is incorporated by reference into
this report from the information set forth under the caption "Executive
Compensation" in the 2000 proxy statement.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information required by this item is incorporated by reference into
this report from the information set forth under the caption "Stock Ownership of
Management and Certain Beneficial Owners" in the 2000 proxy statement.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
The information required by this item is incorporated by reference into
this report from the information set forth under the caption "Certain
Transactions" in the 2000 proxy statement.
-40-
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a) 1. Financial Statements:
See Index to Financial Statements under Item 8 of this Form 10-K.
2. Financial Statement Schedules:
Schedules are omitted because they are not required or are inapplicable
or because the information called for is included in the financial
statements or the notes thereto.
3. Exhibits -- See (c) below
(b) Reports on Form 8-K:
No reports on Form 8-K were filed during the last quarter of the period
covered by this Report.
(c) Exhibits
The following documents are exhibits to this Form 10-K:
-41-
EXHIBIT
NUMBER DESCRIPTION OF DOCUMENT
------ -----------------------
3.1 Amended and Restated Certificate of Incorporation.(5)
3.2 Bylaws.(5)
3.3 Certificate of Designation of the Series A Convertible Preferred
Stock, dated as of December 14, 1994 (Filed as part of Exhibit
10.20).
3.4 Certificate of Designation of the Series B Convertible Preferred
Stock, dated as of December 20, 1996. (13)
3.5 Certificate of Designation of the Series C Junior Participating
Preferred Stock, dated as of October 6, 1997. (16)
4.1 Reference is made to exhibits 3.1, 3.2, 3.3, 3.4, 3.5, 4.3, 4.4, 4.5,
4.6, 4.7, 4.8, 4.9, 4.10, 10.10, 10.12, 10.13, 10.22, 10.24 and
10.41.
4.2 Specimen stock certificate.(1)
4.3 Common Stock Purchase Agreement between the Company and International
Biotechnology Trust plc ("IBT") and Societe Financiere D'Innovation
Inc. ("Sofinov"), dated as of August 18, 1999.(28)
4.4 Registration Rights Agreement between the Company and IBT and
Sofinov, dated as of August 18, 1999.(28)
4.5 Note Purchase Agreement between the Company and Artisan Equity
Limited ("Artisan"), dated as of August 18, 1999.(26)
4.6 5.5% Convertible Senior Subordinated Note Due 2006, in the principal
amount of $6,500,000, issued to Artisan, dated as of August 18,
1999.(26)
4.7 Registration Rights Agreement between the Company and Artisan, dated
as of August 18, 1999.(26)
4.8 Common Stock Purchase Agreement between the Company and Sofinov and
Finsbury Technology Trust ("Finsbury") and Westcoast and Company
("Westcoast"), dated as of October 20, 1999.(30)
4.9 Registration Rights Agreement between the Company and Sofinov and
Finsbury and Westcoast, dated as of October 20, 1999.(30)
4.10 5.5% Convertible Senior Subordinated Note Due 2006, in the principal
amount of $3,500,000, issued to Artisan, dated as of October 20,
1999.(29)
10.1* Form of Indemnification Agreement between the Company and each
director and executive officer.(1)
10.2* Stock Option Plan of the Company, as amended.(1)
10.3* Form of Incentive Stock Option Agreement under the Stock Option
Plan.(1)
10.4* Form of Non-Incentive Stock Option Agreement under the Stock Option
Plan.(1)
10.5* Form of Employee Stock Purchase Plan.(1)
10.6* 1991 Incentive and Compensation Plan of the Company, as amended.(1)
(12)
10.7* Form of Incentive Stock Option Agreement under the 1991 Incentive and
Compensation Plan of the Company.(2)
10.8* Form of Non-Qualified Stock Option Agreement under the 1991 Incentive
and Compensation Plan of the Company.(2)
-42-
EXHIBIT
NUMBER DESCRIPTION OF DOCUMENT
------ -----------------------
10.9* Form of Restricted Stock Purchase Agreement between the Company and
certain individuals or entities, and attached schedule.(1)
10.10 Second Amended and Restated Stock Registration Rights Agreement
between the Company and certain investors and warrantholders named
therein, dated as of February 14, 1991, as amended on March 19, 1991,
November 13, 1991 and December 4, 1991, and supplemental letter
agreement dated December 12, 1991.(1)
10.11 Antibody Option Agreement between the Company and Centocor, Inc.,
dated as of November 7, 1991, with exhibit.(1) (3)
10.12 Warrant to purchase Series B Preferred Stock of the Company
(subsequently converted to Common Stock) issued to Comdisco, Inc. on
June 19, 1990, as amended on January 2, 1992.(1)
10.13 Warrant to purchase Series B Preferred Stock of the Company
(subsequently converted to Common Stock) issued to Praktikerfinans AB
on November 30, 1990, as amended on January 15, 1992.(1)
10.14 Lease Agreement for 3030 Science Park Road, San Diego, California
between the Company and Hartford Accident and Indemnity Company,
dated as of March 28, 1989, as amended on March 23, 1990, May 18,
1990 and May 16, 1991.(1)
10.15 Fourth Lease Amendment to Lease Agreement for 3030 Science Park Road,
San Diego, California between the Company and Hartford Accident and
Indemnity Company, dated as of January 21, 1992.(1)
10.16 Fifth Lease Amendment to Lease Agreement for 3030 Science Park Road,
San Diego, California between the Company and Hartford Accident and
Indemnity Company, dated as of April 15, 1992, Sixth Lease Amendment
dated as of July 16, 1992, Seventh Lease Amendment dated as of
January 18, 1993.(4)
10.17 Assignment of Lease Agreement for 3030 Science Park Road, San Diego,
California from Corvas International, Inc., a California corporation,
to Corvas International, Inc., a Delaware corporation, dated
September 14, 1993.(5)
10.18* Corvas International, Inc. 401(k) Compensation Deferral Savings Plan
and Trust Agreement (Amended and Restated as of January 1, 1989)
(Revised to incorporate amendments to plan).(6)
10.19 Research and License Agreement for Oral Thrombin Inhibitor Drugs
between the Company and Schering Corporation and Schering-Plough
Ltd., dated as of December 14, 1994 (see Exhibits 10.42, 10.44,
10.45, 10.49, 10.50, 10.54 and 10.55).(6) (7)
10.20 Series A Preferred Stock Purchase Agreement between the Company and
Schering Corporation, dated as of December 14, 1994 (Covers the
issuance of Series A and Series B).(6) (7)
10.21 Eighth Lease Amendment to Lease Agreement for 3030 Science Park Road,
San Diego, California between the Company and Hartford Accident and
Indemnity Company, dated as of July 7, 1995.(8)
10.22 Form of Warrant Agreement to purchase Common Stock of the Company
issued to certain individuals affiliated with Ventana Leasing, Inc.
on June 16, 1995.(9)
-43-
EXHIBIT
NUMBER DESCRIPTION OF DOCUMENT
------ -----------------------
10.23 Collaborative Research and Option Agreement between the Company and
Pfizer Inc. and Pfizer Limited, dated as of October 14, 1995.(9) (11)
10.24 Common Stock and Warrant Purchase Agreement between the Company and
certain purchasers, dated as of February 2, 1996, with exhibits.(9)
10.25 Ninth Lease Amendment to Lease Agreement for 3030 Science Park Road,
San Diego, California between the Company and Hartford Accident and
Indemnity Company, dated as of March 15, 1996.(10)
10.26* Employment Agreement by and between the Company and George P. Vlasuk,
dated as of March 18, 1997. (12)
10.27* Employment Agreement by and between the Company and Randall E. Woods,
dated as of March 18, 1997. (12)
10.28 Tenth Lease Amendment to Lease Agreement for 3030 Science Park Road,
San Diego, California between the Company and Hub Properties Trust,
dated as of May 12, 1997.(13)
10.29 License and Collaboration Agreement between the Company and Schering
Corporation, dated as of June 11, 1997 (see Exhibits 10.30, 10.35 and
10.47). (14) (17)
10.30 License and Collaboration Agreement between the Company and
Schering-Plough Ltd., dated as of June 11, 1997 (see Exhibits 10.29,
10.35 and 10.47). (14) (17)
10.31 Option Agreement between the Company and Vascular Genomics Inc.,
dated as of June 29, 1997, with exhibits (see Exhibits 10.52 and
10.53). (14) (31)
10.32 Research and Development Agreement between the Company and Vascular
Genomics Inc., dated as of June 29, 1997, with exhibits (see Exhibits
10.52 and 10.53). (14) (31)
10.33* Amended and Restated Secured Promissory Note between the Company and
Randall E. Woods, dated as of August 28, 1997 (see Exhibits 10.43 and
10.51). (16)
10.34 Rights Agreement between the Company and American Stock Transfer and
Trust Company, dated as of September 18, 1997. (15)
10.35 Letter of Agreement between the Company and Schering Corporation and
Schering- Plough Ltd., dated as of April 16, 1998 (see Exhibits
10.29, 10.30 and 10.47). (18) (19)
10.36 Eleventh Amendment to Lease Agreement for 3030 Science Park Road, San
Diego, California between the Company and Hub Properties Trust, dated
as of April 23, 1998. (18)
10.37 Offer to Amend Warrants to Purchase Shares of Common Stock of the
Company, dated as of June 5, 1998, with certain exhibits thereto.
(20)
10.38 License Agreement between the Company and OCD, dated as of July 22,
1998. (21) (31)
10.39 License Agreement between the Company and LifeScan, Inc., dated as of
July 22, 1998. (21) (31)
-44-
EXHIBIT
NUMBER DESCRIPTION OF DOCUMENT
------ -----------------------
10.40 Agreement for Corvas to Maintain Antibody Agreements, dated as of
July 22, 1998. (21)
10.41 Form of Warrant to Purchase Common Stock of the Company issued to
Biotechnology Value Fund, L.P. and affiliates, dated as of August 3,
1998. (21)
10.42 Termination of Research and License Agreement for Thrombin Research
Program between the Company and Schering Corporation and
Schering-Plough, Ltd., effective August 14, 1998 (see Exhibits 10.19
and 10.45). (21)
10.43* First Amendment to Amended and Restated Secured Promissory Note
between the Company and Randall E. Woods and Nancy Saint Woods, dated
as of September 17, 1998 (see Exhibits 10.33 and 10.51). (21)
10.44 Letter of Agreement between the Company and Schering Corporation and
Schering- Plough Ltd., dated as of December 15, 1998 (see Exhibits
10.19, 10.45, 10.49, 10.50, 10.54 and 10.55). (22) (24)
10.45 Amendment Agreement between the Company and Schering Corporation and
Schering-Plough Ltd., effective as of February 18, 1999 (see Exhibits
10.19 and 10.42). (22) (24)
10.46 Twelfth Amendment to Lease Agreement for 3030 Science Park Road, San
Diego, California between the Company and Hub Properties Trust, dated
as of March 9, 1999. (22)
10.47 Letter of Agreement between the Company and Schering Corporation and
Schering- Plough Ltd., dated as of April 29, 1999 (see Exhibits
10.29, 10.30 and 10.35). (23) (31)
10.48 Thirteenth Amendment to Lease Agreement for 3030 Science Park Road,
San Diego, California between the Company and Hub Properties Trust,
dated as of June 15, 1999. (25)
10.49 Letter of Agreement between the Company and Schering Corporation and
Schering- Plough Ltd., dated as of June 23, 1999 (see Exhibits 10.19,
10.44, 10.45, 10.49, 10.50, 10.54 and 10.55). (25)
10.50 Second Amendment Agreement between the Company and Schering
Corporation and Schering-Plough Ltd., effective as of June 29, 1999
(see Exhibits 10.19, 10.44, 10.45, 10.49, 10.54 and 10.55). (25) (27)
10.51* Second Amendment to Amended and Restated Secured Promissory Note
between the Company and Randall E. Woods and Nancy Saint Woods, dated
as of July 7, 1999 (see Exhibits 10.33 and 10.43). (25)
10.52 Settlement Agreement and Mutual General Release between the Company
and Vascular Genomics Inc. and its stockholders, dated as of July 26,
1999, with certain exhibits thereto. (see Exhibits 10.31, 10.32 and
10.53). (25)
10.53 Amendment to Settlement Agreement and Mutual General Release between
the Company and Vascular Genomics Inc. and its stockholders,
effective as of July 26, 1999. (see Exhibits 10.31, 10.32 and 10.52).
(25)
10.54 Letter of Agreement between the Company and Schering Corporation and
Schering- Plough Ltd., effective as of September 8, 1999 (see
Exhibits 10.19, 10.44, 10.45, 10.49, 10.50 and 10.55). (30)
10.55 Third Amendment Agreement between the Company and Schering
Corporation and Schering-Plough Ltd., effective as of December 7,
1999 (see Exhibits 10.19, 10.44, 10.45, 10.49, 10.50 and 10.54). (31)
21.1 Subsidiary of the Company.(1)
23.1 Independent Auditors' Consent.
24.1 Power of Attorney. Reference is made to page 47.
27.1 Financial Data Schedule.
-45-
- ----------------------------------
(1) Incorporated by reference to Registration Statement on Form S-1 (No.
33-44555), as amended, filed December 13, 1991.
(2) Incorporated by reference to Registration Statement on Form S-8 (No.
33-45607), as amended, filed February 10, 1992.
(3) Portions of this exhibit have been granted confidential treatment
pursuant to an order granted by the Securities and Exchange Commission on
January 30, 1992.
(4) Incorporated by reference to Annual Report on Form 10-K, filed March 30,
1993.
(5) Incorporated by reference to Annual Report on Form 10-K, filed February
23, 1994.
(6) Incorporated by reference to Annual Report on Form 10-K, filed March 30,
1995.
(7) Portions of this exhibit have been granted confidential treatment
pursuant to an order granted by the Securities and Exchange Commission on
May 11, 1995.
(8) Incorporated by reference to Quarterly Report on Form 10-Q, filed
November 13, 1995.
(9) Incorporated by reference to Annual Report on Form 10-K, filed February
28, 1996.
(10) Incorporated by reference to Registration Statement on Form S-1 (No.
333-2644), filed March 25, 1996.
(11) Portions of this exhibit have been granted confidential treatment
pursuant to an order granted by the Securities and Exchange Commission on
April 26, 1996.
(12) Incorporated by reference to Annual Report on Form 10-K, filed March 28,
1997.
(13) Incorporated by reference to Quarterly Report on Form 10-Q, filed May 14,
1997.
(14) Incorporated by reference to Quarterly Report on Form 10-Q, filed August
13, 1997.
(15) Incorporated by reference to Current Report on Form 8-K, filed October 8,
1997.
(16) Incorporated by reference to Quarterly Report on Form 10-Q, filed
November 12, 1997.
(17) Portions of this exhibit have been granted confidential treatment
pursuant to an order granted by the Securities and Exchange Commission on
August 26, 1997.
(18) Incorporated by reference to Quarterly Report on Form 10-Q, filed May 14,
1998.
(19) Portions of this exhibit have been granted confidential treatment
pursuant to an order granted by the Securities and Exchange Commission on
July 10, 1998.
(20) Incorporated by reference to Quarterly Report on Form 10-Q, filed August
12, 1998.
(21) Incorporated by reference to Quarterly Report on Form 10-Q, filed
November 13, 1998.
(22) Incorporated by reference to Annual Report on Form 10-K, filed March 30,
1999.
(23) Incorporated by reference to Quarterly Report on Form 10-Q, filed May 17,
1999.
(24) Portions of this exhibit have been granted confidential treatment
pursuant to an order granted by the Securities and Exchange Commission on
May 28, 1999.
(25) Incorporated by reference to Quarterly Report on Form 10-Q, filed August
13, 1999.
(26) Incorporated by reference to Schedule 13D, filed by Artisan Equity
Limited on August 27, 1999.
(27) Portions of this exhibit have been granted confidential treatment
pursuant to an order granted by the Securities and Exchange Commission on
September 22, 1999.
(28) Incorporated by reference to Registration Statement on Form S-3 (No.
333-87339), filed September 27, 1999.
(29) Incorporated by reference to Schedule 13D, filed by Artisan Equity
Limited on November 5, 1999.
(30) Incorporated by reference to Quarterly Report on Form 10-Q, filed
November 12, 1999.
(31) Confidential treatment has been requested from the Securities and
Exchange Commission for portions of this exhibit.
* Indicates executive compensation plan or arrangement.
-46-
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the registrant has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized.
CORVAS INTERNATIONAL, INC.
Date: March 29, 2000 By: /s/ RANDALL E. WOODS
-------------------------------------
Randall E. Woods
President and Chief Executive Officer
POWER OF ATTORNEY
KNOWN TO ALL PERSONS BY THESE PRESENTS, that each person whose
signature appears below constitutes and appoints Randall E. Woods and Carolyn M.
Felzer, or either of them, his attorney-in-fact, with the full power of
substitution for him in any and all capacities, to sign any amendments to this
Report, and to file the same, with exhibits thereto and other documents in
connection therewith, with the Securities and Exchange Commission, hereby
ratifying and confirming all that said attorneys-in-fact, or his substitute or
substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934,
this Report has been signed by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.
Signatures Titles Date
---------- ------ ----
/s/ RANDALL E. WOODS President, Chief Executive March 29, 2000
- ---------------------------------- Officer and Director
Randall E. Woods (Principal Executive Officer)
/s/ CAROLYN M. FELZER Senior Director of Finance March 29, 2000
- ---------------------------------- (Principal Financial and
Carolyn M. Felzer Accounting Officer)
/s/ M. BLAKE INGLE, PH.D. Chairman of the Board of March 29, 2000
- ---------------------------------- Directors
M. Blake Ingle, Ph.D.
/s/ J. STUART MACKINTOSH Director March 29, 2000
- ----------------------------------
J. Stuart Mackintosh
/s/ BURTON E. SOBEL, M.D. Director March 29, 2000
- ----------------------------------
Burton E. Sobel, M.D.
Director March 29, 2000
- ----------------------------------
Michael Sorell, M.D.
/s/ NICOLE VITULLO Director March 29, 2000
- ----------------------------------
Nicole Vitullo
/s/ GEORGE P. VLASUK, PH.D. Director March 29, 2000
- ----------------------------------
George P. Vlasuk, Ph.D.
-47-
INDEPENDENT AUDITORS' REPORT
The Board of Directors
Corvas International, Inc.:
We have audited the accompanying balance sheets of Corvas International, Inc. as
of December 31, 1999 and 1998, and the related statements of operations,
stockholders' equity, and cash flows for each of the years in the three-year
period ended December 31, 1999. These financial statements are the
responsibility of the Company's management. Our responsibility is to express an
opinion on these financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Corvas International, Inc. as
of December 31, 1999 and 1998, and the results of its operations and its cash
flows for each of the years in the three-year period ended December 31, 1999, in
conformity with generally accepted accounting principles.
/s/ KPMG LLP
San Diego, California
February 4, 2000, except as to Note 12 which is as of March 9, 2000
F-1
CORVAS INTERNATIONAL, INC.
BALANCE SHEETS
(In thousands, except share and per share data)
December 31,
----------------------------
1999 1998
------------- -------------
ASSETS
- ------
Current assets:
Cash and cash equivalents $ 881 $ 611
Short-term debt securities held to maturity and time
deposits, partially restricted (notes 2 and 7) 20,630 17,002
Receivables 316 251
Note receivable from related party (note 10) 278 153
Other current assets 547 411
------------- -------------
Total current assets 22,652 18,428
------------- -------------
Debt issuance costs 127 ---
Property and equipment, net (note 3) 1,110 1,484
------------- -------------
$ 23,889 $ 19,912
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY
- ------------------------------------
Current liabilities:
Accounts payable $ 993 $ 326
Accrued liabilities 1,167 993
Accrued vacation 214 207
------------- -------------
Total current liabilities 2,374 1,526
------------- -------------
Convertible notes payable (note 4) 10,215 ---
Deferred rent 25 ---
Stockholders' equity (notes 5 and 8):
Preferred stock, $0.001 par value, 10,000,000 shares
authorized; issued and outstanding:
Series A Convertible: 1,000,000 shares in 1999 and
1998 (liquidating preference $5 per share) 1 1
Series B Convertible: 250,000 shares in 1999 and 1998
(liquidating preference $8 per share) --- ---
Common stock, $0.001 par value, 50,000,000 shares
authorized; issued and outstanding 17,503,000 shares
in 1999 and 15,098,000 shares in 1998 17 15
Additional paid-in capital 102,127 96,223
Accumulated deficit (90,870) (77,853)
------------- -------------
Total stockholders' equity 11,275 18,386
Commitments and contingencies (notes 7 and 8)
------------- -------------
$ 23,889 $ 19,912
============= =============
See accompanying notes to financial statements.
F-2
CORVAS INTERNATIONAL, INC.
STATEMENTS OF OPERATIONS
(In thousands, except per share data)
Years Ended December 31,
-------------------------------------------
1999 1998 1997
------------- ------------- -------------
REVENUES:
Revenue from collaborative
agreements (note 8) $ 6,088 $ 6,985 $ 5,811
License fees and milestones (note 8) --- 2,795 4,100
Net product sales (note 8) --- 44 374
Royalties (note 8) 190 145 120
Research grants (note 11) 14 --- ---
------------- ------------- -------------
Total revenues 6,292 9,969 10,405
------------- ------------- -------------
COSTS AND EXPENSES:
Research and development (notes 8 and 11) 14,669 15,800 9,705
General and administrative (note 8) 5,320 3,670 4,469
Cost of products sold (note 8) --- 18 194
------------- ------------- -------------
Total costs and expenses 19,989 19,488 14,368
------------- ------------- -------------
Loss from operations (13,697) (9,519) (3,963)
------------- ------------- -------------
OTHER INCOME (EXPENSE):
Interest income 901 1,201 1,510
Interest expense (note 4) (221) --- ---
Other income --- 214 1
------------- ------------- -------------
680 1,415 1,511
------------- ------------- -------------
Net loss and other comprehensive loss $ (13,017) $ (8,104) $ (2,452)
============= ============= =============
Basic and diluted net loss per share $ (0.82) $ (0.56) $ (0.18)
============= ============= =============
Shares used in calculation of basic
and diluted net loss per share 15,842 14,460 13,873
============= ============= =============
See accompanying notes to financial statements.
F-3
CORVAS INTERNATIONAL, INC.
Statements of Stockholders' Equity
For the Three Years Ended December 31, 1999
(In thousands)
Series A Series B
Convertible Convertible
Preferred Stock Preferred Stock Common Stock
-----------------------------------------------------------------------
Shares Amount Shares Amount Shares Amount
----------- ----------- ----------- ----------- ----------- -----------
Balance as of December 31, 1996 1,000 $ 1 250 $ --- 13,717 $ 14
Common stock issued upon exercise of
stock options --- --- --- --- 203 ---
Common stock issued pursuant to employee stock
purchase plan --- --- --- --- 15 ---
Common stock issued in exchange for services --- --- --- --- 15 ---
Net loss --- --- --- --- --- ---
----------- ----------- ----------- ----------- ----------- -----------
Balance as of December 31, 1997 1,000 1 250 --- 13,950 14
Common stock issued upon exercise of
stock options --- --- --- --- 95 ---
Compensation expense recognized pursuant to
issuance of certain stock options for services --- --- --- --- --- ---
Common stock issued pursuant to employee stock
purchase plan --- --- --- --- 28 ---
Common stock issued pursuant to exercise of
warrants, net of issuance costs --- --- --- --- 1,025 1
Net loss --- --- --- --- --- ---
----------- ----------- ----------- ----------- ----------- -----------
Balance as of December 31, 1998 1,000 1 250 --- 15,098 15
Common stock issued for cash, net of issuance
costs --- --- --- --- 2,000 2
Common stock issued upon exercise of
stock options --- --- --- --- 135 ---
Common stock issued pursuant to employee stock
purchase plan --- --- --- --- 20 ---
Common stock issued pursuant to settlement of
contractual option agreement --- --- --- --- 250 ---
Compensation expense recognized pursuant to
issuance of certain stock options for services --- --- --- --- --- ---
Net loss --- --- --- --- --- ---
----------- ----------- ----------- ----------- ----------- -----------
Balance as of December 31, 1999 1,000 $ 1 250 $ --- 17,503 $ 17
=========== =========== =========== =========== =========== ===========
Statements of Stockholders' Equity continued on next page
Statements of Stockholders' Equity, continued
Additional Total
Paid-in Accumulated Stockholders'
Capital Deficit Equity
----------- ----------- -----------
Balance as of December 31, 1996 $ 91,629 $ (67,297) $ 24,347
Common stock issued upon exercise of
stock options 411 --- 411
Common stock issued pursuant to employee stock
purchase plan 71 --- 71
Common stock issued in exchange for services 68 --- 68
Net loss --- (2,452) (2,452)
----------- ----------- -----------
Balance as of December 31, 1997 92,179 (69,749) 22,445
Common stock issued upon exercise of
stock options 190 --- 190
Compensation expense recognized pursuant to
issuance of certain stock options for services 109 --- 109
Common stock issued pursuant to employee stock
purchase plan 99 --- 99
Common stock issued pursuant to exercise of
warrants, net of issuance costs 3,646 --- 3,647
Net loss --- (8,104) (8,104)
----------- ----------- -----------
Balance as of December 31, 1998 96,223 (77,853) 18,386
Common stock issued for cash, net of issuance
costs 4,865 --- 4,867
Common stock issued upon exercise of
stock options 231 --- 231
Common stock issued pursuant to employee stock
purchase plan 72 --- 72
Common stock issued pursuant to settlement of
contractual option agreement 703 --- 703
Compensation expense recognized pursuant to
issuance of certain stock options for services 33 --- 33
Net loss --- (13,017) (13,017)
----------- ----------- -----------
Balance as of December 31, 1999 $ 102,127 $ (90,870) $ 11,275
=========== =========== ===========
See accompanying notes to financial statements.
F-4
CORVAS INTERNATIONAL, INC.
STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
Years ended December 31,
-------------------------------------------
1999 1998 1997
------------- ------------- -------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (13,017) $ (8,104) $ (2,452)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization 546 604 618
Amortization of premiums and discounts on investments (725) (819) (419)
Non-cash interest expense on convertible notes payable 221 --- ---
Stock compensation expense 760 124 68
(Gain)/loss on disposal of property and equipment 74 (128) ---
Change in assets and liabilities:
(Increase) decrease in receivables (65) 38 149
Increase in other current assets (136) (71) (28)
Increase (decrease) in accounts payable, accrued
liabilities and accrued vacation 848 413 (152)
Increase in deferred rent 25 --- ---
Decrease in deferred revenue --- (4,656) (344)
------------- ------------- -------------
Net cash used in operating activities (11,469) (12,599) (2,560)
------------- ------------- -------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of investments held to maturity (30,812) (39,462) (43,518)
Proceeds from maturity of investments held to maturity 27,903 47,355 46,255
Purchases of property and equipment (246) (857) (837)
Proceeds from sale of property and equipment --- 209 ---
Repayments from (loans to) related party (125) --- 47
------------- ------------- -------------
Net cash provided by (used in) investing activities (3,280) 7,245 1,947
------------- ------------- -------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments under capital lease obligation --- --- (27)
Net proceeds from issuance of common stock 5,146 3,921 482
Net proceeds from issuance of convertible notes payable 9,873 --- ---
------------- ------------- -------------
Net cash provided by financing activities 15,019 3,921 455
------------- ------------- -------------
Net increase (decrease) in cash and cash equivalents 270 (1,433) (158)
Cash and cash equivalents at beginning of period 611 2,044 2,202
------------- ------------- -------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 881 $ 611 $ 2,044
============= ============= =============
See accompanying notes to financial statements.
F-5
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements
December 31, 1999 and 1998
(l) The Company
-----------
Corvas International, Inc. (the "Company") was incorporated on March 27,
1987 under the laws of the State of California. In July 1993, the Company
reincorporated in the State of Delaware. The Company is engaged in the
design and development of a new generation of therapeutic agents for
cardiovascular, cancer, stroke and other major diseases.
(2) Summary of Significant Accounting Policies
------------------------------------------
(a) Cash Equivalents:
-----------------
Cash equivalents consist of investments in a short-term government
fund and a high quality money market fund. Cash equivalents are
stated at cost, which approximates market value.
(b) Short-term Debt Securities Held to Maturity and Time Deposits:
--------------------------------------------------------------
Short-term debt securities consist primarily of government-backed
debt instruments, as well as debt instruments of corporations with
strong credit ratings. Short-term debt securities are carried at
amortized cost which approximates market value and mature at
various dates through July 14, 2000. At December 31, 1999 and
1998, time deposits of $221,000 and $60,000, respectively, were
restricted related to the facility lease. See Note 7.
The Company has the ability and intent to hold its investments
until their maturity and, therefore, records its investments at
amortized cost, adjusted for the amortization or accretion of
premiums or discounts.
(c) Depreciation and Amortization:
------------------------------
Depreciation is provided using the straight-line method over
estimated useful lives of three to five years. Leasehold
improvements are amortized on a straight-line basis over the
shorter of the lease term or estimated useful life of the asset.
(d) Research and Development Costs:
-------------------------------
Research and development costs are expensed in the period
incurred.
(e) Patents:
--------
Costs to obtain and maintain patents are expensed as incurred.
(f) Net Loss per Share:
-------------------
Under Statement of Financial Accounting Standards No. 128,
"Earnings per Share" ("SFAS 128"), basic and diluted net loss per
share are required to be presented. Basic net loss per share is
calculated using the weighted-average number of common shares
outstanding during the period, while diluted net loss per share
also includes potential common shares outstanding. Potential
common equivalent shares from convertible securities, stock
options and warrants are excluded from the calculation of diluted
loss per share since the effect of their inclusion would be
anti-dilutive.
F-6
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements, Continued
Options, warrants and convertible preferred stock totaling
5,695,000, 5,176,000 and 6,324,000 shares were excluded from the
calculation of net loss per share for the years ended December 31,
1999, 1998 and 1997, respectively. In addition, 3,129,000 shares
from the assumed conversion of the 5.5% convertible senior
subordinated notes issued in 1999 (see Note 4) were excluded for
the year ended December 31, 1999 since the effect of their
inclusion would be anti-dilutive.
(g) Revenue Recognition:
--------------------
Revenue from collaborative agreements is generally recognized over
the term of the agreement; any advance payments received in excess
of amounts earned are classified as deferred revenue.
Non-refundable license fees and milestones are generally
recognized upon receipt of license fees or achievement of certain
milestones. Research grant revenue is recognized as research is
performed under the terms of the grant.
(h) Accounting for Stock-Based Compensation:
----------------------------------------
As permitted by Statement of Financial Accounting Standards No.
123, "Accounting for Stock-Based Compensation" ("SFAS 123"), the
Company has elected to retain its current intrinsic value-based
method as prescribed in Accounting Principles Board ("APB")
Opinion No. 25, "Accounting for Stock Issued to Employees" and
related interpretations. The Company discloses the pro forma
effects of using the fair value-based method to account for its
stock-based compensation in its financial statements.
(i) Income Taxes:
-------------
Income taxes are accounted for under the asset and liability
method. Deferred tax assets and liabilities are recognized for the
estimated future tax consequences attributable to differences
between the financial statement carrying amounts of existing
assets and liabilities and their respective tax bases and net
operating loss and tax credit carryforwards. Deferred tax assets
and liabilities are measured using enacted tax rates expected to
apply to taxable income in the years in which those temporary
differences are expected to be recovered or settled. The effect on
deferred tax assets and liabilities of a change in tax rates is
recognized in income in the period that includes the enactment
date.
(j) Use of Estimates:
-----------------
The preparation of financial statements in conformity with
generally accepted accounting principles requires management of
the Company to make a number of estimates and assumptions that
affect the amounts reported in the financial statements and
accompanying footnotes. Actual results could differ from those
estimates.
(k) Fair Value of Financial Instruments:
------------------------------------
Statement of Financial Accounting Standards No. 107, "Disclosures
about Fair Value of Financial Instruments" ("SFAS 107"), defines
the fair value of a financial instrument as the amount at which
the instrument could be exchanged in a current transaction between
willing parties. The carrying amount of cash and cash equivalents,
short-term debt securities held to maturity and time deposits,
receivables, other current assets, accounts payable, accrued
liabilities and accrued vacation, included in the accompanying
balance sheets, approximate the estimated fair value of those
instruments because of their short-term nature. The carrying value
of the convertible notes payable approximates the fair value due
to the recency of their issuance. The fair value of the note
receivable from related party cannot be determined due to its
related party nature.
F-7
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements, Continued
(l) Impairment and Disposition of Long-Lived Assets:
------------------------------------------------
Statement of Financial Accounting Standards No. 121, "Accounting
for the Impairment of Long-Lived Assets and for Long-Lived Assets
to be Disposed Of" ("SFAS 121") requires losses from impairment of
long-lived assets used in operations to be recorded when
indicators of impairment are present and the undiscounted cash
flows estimated to be generated by those assets before interest
are less than the assets' carrying amount. The Company
periodically evaluates the carrying value of long-lived assets to
be held and used when events and circumstances indicate that the
carrying amount of an asset may not be recovered.
(m) Segment Reporting:
------------------
Statement of Financial Accounting Standards No. 131, "Disclosures
About Segments of an Enterprise and Related Information" ("SFAS
131"), establishes reporting standards for a Company's operating
segments and related disclosures about its products, services,
geographic areas and major customers. An operating segment is
defined as a component of an enterprise that engages in business
activities from which it may earn revenues and incur expenses, and
about which separate financial information is regularly evaluated
by Management in deciding how to allocate resources. The Company
believes that it operates in a single segment, biopharmaceuticals.
(3) Property and Equipment
----------------------
Property and equipment are recorded at cost and are summarized as follows
(in thousands).
December 31,
----------------------------
1999 1998
------------- -------------
Machinery and equipment $ 4,321 $ 4,339
Furniture and fixtures 143 143
Leasehold improvements 866 838
------------- -------------
Total property and equipment 5,330 5,320
Less accumulated depreciation (4,220) (3,836)
------------- -------------
$ 1,110 $ 1,484
============= =============
F-8
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements, Continued
(4) Convertible Notes Payable
-------------------------
In August 1999, Corvas issued and sold in a private financing 1,300,000
shares of Common Stock for $2.50 per share (see Note 5) and a 5.5%
convertible senior subordinated note (the "First Convertible Note"), due
in August 2006, in an original principal amount of $6,500,000. Net
proceeds of $6,377,000 were raised through the issuance of the First
Convertible Note and net proceeds of $3,139,000 from the issuance of
Common Stock. Upon maturity, the First Convertible Note will have an
accreted value of $9,503,000. Interest on the outstanding principal
amount of the First Convertible Note accretes at 5.5% per annum from
August 1999 to August 2006, compounded semi-annually, with interest
payable upon redemption or conversion. At the Company's option, the
accretion may be paid in cash or in Corvas Common Stock priced at the
then-current market price. The Company has agreed to pay any applicable
withholding taxes that may be required in connection with the accretion,
which are estimated and accrued at 30% of the annual accretion. At the
option of the note holder, the principal of the First Convertible Note is
convertible into shares of Corvas Common Stock at $3.25 per share,
subject to adjustment for certain changes in capital or reorganizations
and subject to adjustment if Corvas sells additional securities for less
than $2.50 per share before August 18, 2000. 2,924,000 shares of Common
Stock have been reserved for the potential conversion of the First
Convertible Note. Corvas may call the First Convertible Note for
redemption anytime after August 18, 2002.
In October 1999, Corvas issued and sold in a private financing 700,000
shares of Common Stock for $2.50 per share (see Note 5) and an additional
5.5% convertible senior subordinated note (the "Second Convertible
Note"), also due in August 2006, in an original principal amount of
$3,500,000. Estimated net proceeds of $3,496,000 and $1,728,000,
respectively, were raised through the issuance of the Second Convertible
Note and the additional Common Stock. Upon maturity, the Second
Convertible Note will have an accreted value of $5,069,000. Interest on
the outstanding principal of the Second Convertible Note accretes at 5.5%
per annum from October 1999 to August 2006, compounded semi-annually,
with interest payable upon redemption or conversion. Otherwise, the
conversion price and all other terms of the Second Convertible Note are
identical to those of the First Convertible Note. 1,560,000 shares of
Common Stock have been reserved for the potential conversion of the
Second Convertible Note.
Interest expense of $221,000 was recorded for the year ended December 31,
1999 related to both of the convertible notes.
(5) Stockholders' Equity
--------------------
(a) Preferred Stock:
----------------
In December 1996, in conjunction with a strategic alliance with
Schering-Plough Corporation ("Schering-Plough") (see Note 8), the
Company issued 250,000 shares of Series B Convertible Preferred
Stock, which resulted in net proceeds of $2,000,000. Each share of
Series B Preferred Stock is convertible into one share of the
Company's Common Stock, and will automatically convert if the
market price of the Company's Common Stock for 10 consecutive
trading days exceeds $12.00 per share. As a result, 250,000 shares
of Common Stock have been reserved for the potential conversion of
Series B Preferred Stock. Each share of Series B Preferred Stock
is entitled to a fixed, cumulative dividend of $0.64 per share per
annum, when and if declared by the Board of Directors. No such
dividends have been declared. In addition, each share is entitled
to one vote and has a liquidating preference of $8.00 plus any
declared and unpaid dividends. See Note 12.
F-9
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements, Continued
Also in conjunction with its strategic alliance with
Schering-Plough, the Company issued 1,000,000 shares of Series A
Convertible Preferred Stock in December 1994, which resulted in
net proceeds of $4,864,000. Each share of Series A Preferred Stock
is convertible into one share of the Company's Common Stock, and
will automatically convert if the market price of the Company's
Common Stock for 10 consecutive trading days exceeds $7.50 per
share. As a result, 1,000,000 shares of Common Stock have been
reserved for the potential conversion of Series A Preferred Stock.
Each share of Series A Preferred Stock is entitled to a fixed,
cumulative dividend of $0.40 per share per annum, when and if
declared by the Board of Directors. No such dividends have been
declared. In addition, each share is entitled to one vote and has
a liquidating preference of $5.00 plus any declared and unpaid
dividends. See Note 12.
(b) Common Stock:
-------------
In October 1999, the Company issued a total of 700,000 shares of
Common Stock as part of a private financing consisting of Common
Stock and a $3,500,000 convertible senior subordinated note. See
Note 4. In August 1999, the Company issued a total of 1,300,000
shares of Common Stock as part of a private financing consisting
of Common Stock and a $6,500,000 convertible senior subordinated
note. See Note 4. Net proceeds of $1,728,000 and $3,139,000 were
raised from the sale of Common Stock in the October and August
1999 financings, respectively.
In August 1999, the Company issued a total of 250,000 shares of
Common Stock to the stockholders of Vascular Genomics Inc. ("VGI")
upon termination of an option held by Corvas to acquire all of the
stock of VGI. See Note 8.
In July 1998, the Company issued a total of 1,025,000 shares of
Common Stock pursuant to the exercise of certain warrants that
were acquired in February 1996 by a group of institutional
investors, which resulted in net proceeds of $3,647,000.
(c) Stock Option Plans:
-------------------
The Company has several plans and agreements under which incentive
stock options, non-statutory stock options, stock appreciation
rights, restricted stock awards, dividend equivalents, performance
awards and stock payments can be granted to key personnel,
including officers, directors and outside consultants. The grants
are authorized by the Compensation and Stock Option Committee of
the Board of Directors. A total of 3,151,000 options are
authorized for issuance as of December 31, 1999, and 635,000
shares are reserved for future grant.
F-10
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements, Continued
Generally options have a term of 10 years and become exercisable
over a four-year period beginning one year from the date of grant
at a price per share equal to the fair market value on the date of
grant, except for annual grants to outside directors which have an
exercise price equal to 85% of the fair market value on the date
of grant. Most options granted after December 1, 1994 vest 25% at
the end of the first year and 6.25% each quarter thereafter.
Activity under these plans and agreements from 1997 through 1999
is as follows (in thousands, except per share data):
Number of Shares Weighted-Average
Under Option Exercise Price per Share
---------------- ------------------------
Outstanding, December 31, 1996 1,654 $ 3.51
Granted 648 $ 4.70
Exercised (203) $ 2.03
Cancelled (34) $ 4.54
----------
Outstanding, December 31, 1997 2,065 $ 4.01
Granted 178 $ 4.10
Exercised (95) $ 1.99
Cancelled (205) $ 4.73
----------
Outstanding, December 31, 1998 1,943 $ 4.04
Granted 811 $ 2.84
Exercised (180) $ 1.99
Cancelled (340) $ 3.92
----------
Outstanding, December 31, 1999 2,234 $ 3.79
==========
As of December 31, 1999, the range of exercise prices of options
outstanding was $0.88 - $7.06 and the weighted-average remaining
contractual life of these options was 7.5 years. The number of
options exercisable at December 31, 1999, 1998 and 1997 was
1,128,000, 1,234,000 and 875,000, respectively, and the
weighted-average exercise price of those options was $4.27, $3.80
and $3.36, respectively.
(d) Stock-Based Compensation:
-------------------------
The Company accounts for its stock option plans in accordance with
the recognition provisions of APB 25 and related interpretations
for stock grants to employees. Accordingly, stock compensation
expense is recorded on the date of grant only when options are
granted to consultants or when the current market price of the
underlying stock exceeds the exercise price.
The Company has adopted the disclosure-only provisions of SFAS
123. If the Company had determined compensation cost based on the
fair value at the grant date for its stock options under SFAS 123,
the Company's net loss and net loss per share would have been
increased to the pro forma amounts indicated below (in thousands,
except per share data).
1999 1998 1997
----------- ----------- -----------
Net loss - As reported $ (13,017) $ (8,104) $ (2,452)
Net loss - Pro forma $ (13,975) $ (9,832) $ (4,398)
Basic and diluted net loss per share - As reported $ (0.82) $ (0.56) $ (0.18)
Basic and diluted net loss per share - Pro forma $ (0.88) $ (0.68) $ (0.32)
F-11
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements, Continued
The per share weighted-average fair market value of stock options
granted during 1999, 1998 and 1997 at an exercise price equal to
the fair market value on the date of grant was $2.85, $4.24 and
$3.23, respectively, using the Black-Scholes option-pricing model.
The per share weighted-average fair market value of stock options
granted during 1999, 1998 and 1997 at an exercise price less than
the fair market value on the date of grant was $2.39, $3.61 and
$4.97 on the date of grant.
The following weighted-average assumptions were used in
calculating compensation cost for stock options under SFAS 123.
1999 1998 1997
------------- ------------- -------------
Expected dividend yield 0% 0% 0%
Risk-free interest rate 5.16% 5.55% 6.24%
Expected life 7.59 years 8.29 years 7.47 years
Expected volatility 74.95% 75.07% 87.63%
(e) Employee Stock Purchase Plan:
-----------------------------
In December 1991, the Company adopted an employee stock purchase
plan that provides for the issuance of up to 150,000 shares of
Common Stock. The plan is intended to qualify under Section 423 of
the Internal Revenue Code and is for the benefit of qualifying
employees, as designated by the Compensation and Stock Option
Committee of the Board of Directors. Under the terms of the plan,
participating employees are eligible to have a maximum of 10% of
their compensation withheld through payroll deductions to purchase
shares of Common Stock at the lower of 85% of (i) the fair market
value at the beginning of each offering period or (ii) the fair
market value on predetermined dates. As of December 31, 1999,
121,000 shares of Common Stock have been issued pursuant to this
plan.
(f) Warrants:
---------
In conjunction with a private placement of equity securities in
February 1996, the Company issued 3,000,000 warrants to purchase
an equal number of shares of Common Stock. The warrants are
exercisable over a six-year period ending February 2002. The stock
purchase price of these warrants was originally $6.00 per share.
In July 1998, the Company issued a total of 1,025,000 shares of
Common Stock pursuant to an offer for the early exercise of these
warrants at an exercise price of $3.59 per share. Pursuant to the
terms of these warrants, the stock purchase price and the number
of warrants outstanding are adjusted upon the issuance of
additional shares of Common Stock at less than the $6.00 exercise
price. In accordance with such adjustment, as of December 31,
1999, 2,203,000 of these warrants remain outstanding at an
exercise price of $5.38 per share. See Note 12.
In conjunction with the negotiation of equipment leases entered
into in 1990, the Company issued warrants to purchase 9,000 shares
of Preferred Stock (subsequently converted to Common Stock) to the
lessors in lieu of security deposits. The warrants are exercisable
at $6.13 or $7.00 per share over a period of ten years from the
inception of the leases. As of December 31, 1999, none of these
warrants had been exercised.
F-12
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements, Continued
(g) Stock Award:
------------
In November 1997, the Company issued 15,000 shares of Common Stock
to an employee in exchange for services rendered, for which a
charge of $68,000 was recorded in the accompanying statements of
operations.
(h) Stockholder Rights Plan:
------------------------
In September 1997, the Company adopted a stockholder rights plan
and declared a dividend distribution of one preferred share
purchase right (a "Right") for each outstanding share of Common
Stock ("Common Shares"), effective for stockholders of record as
of October 15, 1997 ("Record Date"). The Rights also attach to new
Common Shares issued after the Record Date. Each Right entitles
the registered holder to purchase from the Company one
one-hundredth of a share of Series C Junior Participating
Preferred Stock, par value $0.001, at an exercise price of $50
(the "Purchase Price"). The Rights will become exercisable only if
a person or group acquires 20% or more of the Corvas Common Stock
or announces a tender offer for 20% or more of the Common Stock.
If the Rights become exercisable, all holders of Rights, except
the acquirer, will be entitled to acquire for the Purchase Price
that number of Common Shares having a market value of two times
the Purchase Price of the Right, in lieu of purchasing Series C
Junior Participating Preferred Stock. This Right will commence on
the date of public announcement that a person has become an
Acquiring Person (as defined in the Rights Agreement) or the
effective date of a registration statement relating to
distribution of the Rights, if later, and terminate 60 days later
(subject to certain provisions in the Rights Agreement).
The Rights will expire on September 18, 2007, unless exchanged or
redeemed prior to that date. Until a Right is exercised, the
holder will have no rights as a stockholder of the Company,
including, without limitation, the right to vote or to receive
dividends.
(6) Income Taxes
------------
The Company has no net, taxable temporary differences that would require
recognition of deferred tax liabilities and, due to the uncertainty of
future realizability, has recorded a valuation allowance against any net
deferred tax assets for deductible temporary differences, tax operating
loss carryforwards and tax credits. The Company increased its valuation
allowance by approximately $5,992,000, $4,160,000 and $1,100,000 for the
years ended December 31, 1999, 1998 and 1997, respectively, primarily as
a result of the increase in tax operating loss carryforwards.
At December 31, 1999, the Company had available net operating loss
carryforwards of approximately $86,300,000 for federal income tax
reporting purposes that begin to expire in 2002. The net operating loss
carryforwards for state purposes, which expire five years after
generation, are approximately $45,600,000. The Company has unused
research and development tax credits for federal income tax purposes of
$4,100,000 at December 31, 1999.
In accordance with Internal Revenue Code Section 382, the annual
utilization of net operating loss carryforwards and credits existing
prior to a change in control may be limited.
F-13
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements, Continued
(7) Commitments
-----------
(a) Lease Commitments:
------------------
The Company currently leases its principal facility under an
operating lease that expires in September 2006. The lease provides
for escalating rent payments over the term of the lease. For
financial reporting purposes, rent expense is recognized on a
straight-line basis over the lease term. Accordingly, rent expense
recognized in excess of cash rent paid is reflected as deferred
rent. Total rent expense recognized under this lease for the years
ended December 31, 1999, 1998 and 1997 was $1,013,000, $970,000
and $924,000, respectively.
In 1994, the Company entered into a capital equipment lease for
certain equipment in the amount of $221,000, to be paid over 36
months. The amortization expense on this lease for the year ended
December 31, 1997 was $15,000.
The annual future minimum commitments under the facility lease for
years ending December 31 are as follows (in thousands).
2000 $ 891
2001 923
2002 955
2003 988
2004 1,023
Thereafter 1,873
-------------
Total minimum lease payments $ 6,653
=============
(b) Letter of Credit:
-----------------
The Company has an unused standby letter of credit in the amount
of $221,000 that expires on September 30, 2000, with provisions
for annual renewal. This letter of credit, collateralized by a
$221,000 time deposit, is pledged in lieu of a security deposit
against the principal facility lease.
(8) Collaborative Agreements
------------------------
In July 1999, the Company, VGI and the stockholders of VGI entered into a
Settlement Agreement and Mutual General Release ("Settlement Agreement")
that terminated the Company's option to acquire all of the stock of VGI
in exchange for Corvas Common Stock or, in certain circumstances, a
combination of cash and Common Stock. The option agreement and a related
research and development agreement were originally entered into in June
1997. Upon expiration or cancellation of the three-year option, VGI had
the right to put 19.9% of its outstanding stock to the Company for
$3,960,000 in Corvas Common Stock. In addition, during the option period,
Corvas funded research and other related costs involved in further
developing the technology. Pursuant to the Settlement Agreement, the
Company agreed to pay VGI the sum of $1,200,000 and to deliver to VGI's
stockholders 250,000 shares of the Company's Common Stock. Also pursuant
to the Settlement Agreement, VGI agreed to deliver to the Company shares
of VGI stock equal to 6.5% of VGI's outstanding shares. The accompanying
statements of operations include $400,000, $960,000 and $480,000 of
revenue from collaborative agreements in 1999, 1998 and 1997,
respectively, attributable to VGI. In addition, included in general and
administrative expenses on the accompanying statements of operations in
1999 is the $1,200,000 cash payment, as well as $703,000 for the fair
value of the Common Stock issued.
F-14
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements, Continued
In June 1997, the Company entered into a license and collaboration
agreement with Schering-Plough that covers the design and development of
orally-active inhibitors of a key protease necessary for hepatitis C
virus replication. Under the terms of this agreement, Schering-Plough
received an exclusive worldwide license for products developed from
Corvas compounds under the agreement. Schering-Plough is responsible for
all development, manufacturing and marketing of any resultant products.
In each of 1999 and 1998, the Company recognized $1,575,000 of revenue
from collaborative agreements attributable to this collaboration. Revenue
recognized in 1997 included $250,000 of license fees and $919,000 of
revenue from collaborative agreements. The initial term of the research
program was one year; Schering-Plough has exercised both of its options
to extend funding through May 2000. The Company may also receive
milestone payments as well as royalty payments on product sales if
products are successfully commercialized from this agreement.
In October 1995, the Company entered into a research and option agreement
of up to eighteen months with Pfizer Inc. ("Pfizer") to collaborate on
the development of rNIF, now known by Pfizer as UK-279,276, an
anti-inflammatory agent with therapeutic potential for stroke and other
indications. The option period concluded in October 1996, but Pfizer
extended its option and began to make monthly payments of $125,000
through January 1997 to retain its option rights. In February 1997,
Pfizer exercised its option to enter into an exclusive license and
development agreement on this program. The accompanying statements of
operations reflect revenue from collaborative agreements pursuant to this
collaboration of $113,000 and $450,000 in 1999 and 1998, respectively, as
well as a $1,000,000 milestone earned in 1998 upon commencement of a
Phase I trial for rNIF. Upon exercise of the option in 1997, Pfizer paid
the Company $1,000,000 due upon execution of the agreement, less $200,000
applied from amounts paid to extend the option period from October 1996
to January 1997. Revenue recognized in 1997 included license fees of
$850,000, $800,000 of which was paid upon exercise of the option and
$50,000 which was applied from the January 1997 payment to extend the
option period. Also included in the 1997 statements of operations was
$412,000 of revenue from collaborative agreements recognized as a result
of a portion of the option extension payment from January and the
research funding earned in 1997. Pfizer received an exclusive, worldwide
license to further develop, manufacture and market UK-279,276 as a
therapeutic agent, and is responsible for funding all further development
of UK-279,276, including costs associated with clinical trials and
limited activities at Corvas. Pfizer agreed to compensate the Company for
certain costs of research and preclinical development of UK-279,276 over
a two-year period ending March 31, 1999. The Company may also receive
additional milestone payments as well as royalty payments on product
sales if products are successfully commercialized from this agreement.
In December 1994, the Company entered into a strategic alliance agreement
with Schering-Plough to collaborate on the discovery and
commercialization of orally-active thrombin inhibitor drugs for the
prevention and treatment of chronic cardiovascular disorders. Under the
terms of the agreement, Schering-Plough compensated the Company for
certain costs of research and preclinical development of thrombin
inhibitors over a two-year period that ended December 31, 1996. In June
1998, the Company recognized a $1,000,000 milestone payment from
Schering-Plough upon commencement of a Phase I trial for an oral thrombin
inhibitor. In January 1997, the Company received a $3,000,000 milestone
payment upon selection of a clinical development compound in this
program. In August 1998, the Company and Schering-Plough agreed to
terminate this collaboration.
Under a separate agreement also completed in December 1994,
Schering-Plough purchased 1,000,000 shares of Series A Convertible
Preferred Stock of the Company, which resulted in net proceeds of
$4,864,000. See Note 12.
F-15
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements, Continued
In conjunction with the agreements completed in December 1994,
Schering-Plough acquired an exclusive option to expand the alliance to
include a second blood clotting enzyme, Factor Xa. This option was
exercised in December 1996. Under the terms of this agreement,
Schering-Plough agreed to compensate the Company for certain costs of
research and preclinical development of coagulation Factor Xa inhibitors
over a minimum two-year period that originally ended December 31, 1998.
In December 1998 and again in September and December of 1999,
Schering-Plough extended this program, which is presently funded through
December 2000. The accompanying statements of operations reflect revenue
from collaborative agreements pursuant to this collaboration of
$4,000,000 in each of the years 1999, 1998 and 1997. Exercise of this
option also resulted in the purchase of 250,000 shares of Series B
Convertible Preferred Stock in 1996, which yielded net proceeds of
$2,000,000. The Company may also receive milestone payments as well as
royalty payments on product sales if products are successfully
commercialized from this agreement. Schering-Plough, which is responsible
for preclinical development, all clinical trials and regulatory
activities, received exclusive worldwide marketing rights for any
resulting Factor Xa inhibitors. The Company retained certain
manufacturing rights.
In November 1998, the Company entered into license agreements with two
affiliates of Johnson & Johnson related to recombinant tissue factor,
superceding earlier agreements entered in June 1992. In addition to
transferring the Company's manufacturing activities to these affiliates
of Johnson & Johnson, certain specialized equipment was also sold. The
accompanying statements of operations reflect 1998 license fee revenue of
$795,000 and other income of $209,000 pursuant to these agreements. Net
product sales attributable to affiliates of Johnson & Johnson for the
years ended December 31, 1998 and 1997 were $26,000 and $285,000,
respectively. The agreements continue to provide for royalties to be paid
based on unit sales of tissue factor. For the years ended December 31,
1999, 1998 and 1997, these royalties amounted to $190,000, $145,000 and
$120,000, respectively.
The Company has also entered into research and licensing agreements with
universities and other research institutions which have required the
Company to make royalty payments for the years ended December 31, 1998
and 1997 of $11,000 and $16,000, respectively.
(9) Employee Benefits Plan
----------------------
Effective January 1, 1988, the Board of Directors approved the Corvas
401(k) Compensation Deferral Savings Plan ("The Plan"), adopting
provisions of the Internal Revenue Code Section 401(k). The Plan was
approved by the IRS in 1989, and was amended and restated in 1995. The
Plan is for the benefit of all qualifying employees, and permits employee
voluntary contributions, qualified nonelective contributions and company
profit-sharing contributions. No employer contributions have been
approved by the Board of Directors through December 31, 1999.
(10) Related Party Transaction
-------------------------
The note receivable from related party as of December 31, 1999 and 1998
consists of a loan, evidenced by a promissory note, granted to an
executive officer of the Company in connection with the officer's
relocation to San Diego. At December 31, 1998, the balance was $153,000.
In July 1999, based on additional borrowing, the principal amount was
increased to $278,000. This note bears no interest and is due and payable
in full on the earliest of (i) August 28, 2000, (ii) the settlement or
other final determination of a lawsuit related to the executive officer's
residence, or (iii) within 90 days of the executive officer's termination
of employment with the Company.
F-16
CORVAS INTERNATIONAL, INC.
Notes to Financial Statements, Continued
(11) Research Grant
--------------
In 1999, $14,000 of research grant revenue was recorded pursuant to a
Small Business Innovation Research (SBIR) grant from the National
Institute for Allergy and Infectious Disease. The related expenses, which
equal research grant revenues, are recorded as research and development
expenses in the accompanying statements of operations.
(12) Subsequent Events
-----------------
In January 2000, one of the warrant holders from the February 1996
financing exercised their warrants, which resulted in net proceeds of
$1,200,000. See Note 5.
In February 2000, another warrant holder from the February 1996 financing
exercised their warrants, which resulted in net proceeds of $8,400,000.
See Note 5.
Also in February 2000, the 1,000,000 shares of Series A Convertible
Preferred Stock and 250,000 shares of Series B Convertible Preferred
Stock held by Schering-Plough automatically converted into Common Stock
after the market price of the Company's Common Stock exceeded $7.50 and
$12.00 per share, respectively, for 10 consecutive trading days. See Note
5.
In March 2000, a third warrant holder from the February 1996 financing
exercised their warrants, which resulted in net proceeds of $1,050,000.
See Note 5.
Pro forma basic and diluted net loss per share, giving effect as of
January 1, 1999 to the 3,230,000 shares of Common Stock issued pursuant
to the above subsequent events, was $(0.68). At December 31, 1999 pro
forma cash and cash equivalents, time deposits and debt securities would
have been $32,161,000. Also as of December 31, 1999, Preferred Stock,
Common Stock and Additional Paid-in Capital were $0, $20,000 and
$112,774,000, respectively, on a pro forma basis. No other balance sheet
or statement of operations amounts were affected as a result of these
subsequent events.
F-17